17. Referanser

Aberle, D. R., Adams, A. M., Berg, C. D., Black, W. C., Clapp, J. D., Fagerstrom, R. M., Gareen, I. F., Gatsonis, C., ... National Lung Screening Trial Research Team (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 365(5), 395-409.

Aberle, D. R., DeMello, S., Berg, C. D., Black, W. C., Brewer, B., Church, T. R., Clingan, K. L., Duan, F., ... National Lung Screening Trial Research Team (2013). Results of the two incidence screenings in the National Lung Screening Trial. New England Journal of Medicine, 369(10), 920-31.

Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., ... Caravaggio Investigators (2020). Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. New England Journal of Medicine, 382(17), 1599-1607.

Aguilar, E., Gainor, J., Kravets, S., Khosrowjerdi, S., Lydon, C., Adeni, A., Subegdjo, S., Rizvi, H., ... Awad, M. (2018). Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 0-89% vs 90-100%. Journal of Thoracic Oncology, 13(10), S367-S368.

Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi, A. T., Shepherd, F. A., Smith, C., Chen, Y., Livingston, R. B., ... Cox, J. D. (2009). Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet, 374(9687), 379-86.

Aldea, M., Marinello, A., Duruisseaux, M., Zrafi, W., Conci, N., Massa, G., Metro, G., Monnet, I., ... Besse, B. (2023). RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. Journal of Thoracic Oncology, 18(5), 576-586.

Ali, M. S., Trick, W., Mba, B. I., Mohananey, D., Sethi, J., & Musani, A. I. (2017). Radial endobronchial ultrasound for the diagnosis of peripheral pulmonary lesions: A systematic review and meta-analysis. Respirology, 22(3), 443-453.

Al-Ibraheem, A., Hirmas, N., Fanti, S., Paez, D., Abuhijla, F., Al-Rimawi, D., Al-Rasheed, U., Abdeljalil, R., ... Mansour, A. (2021). Impact of (18)F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC. BMC Medical Imaging, 21(1), 49.

Al-Sahaf, M., & Lim, E. (2015). The association between surgical volume, survival and quality of care. Journal of Thoracic Disease, 7(Suppl 2), S152-5.

Anderson, G., & Takahama, Y. (2012). Thymic epithelial cells: working class heroes for T cell development and repertoire selection. Trends in Immunology, 33(6), 256-63.

Anderson, K. L., Mulvihill, M. S., Speicher, P. J., Yerokun, B. A., Gulack, B. C., Nussbaum, D. P., Harpole, D. H., D'Amico, T. A., ... Hartwig, M. G. (2017). Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. Annals of Thoracic Surgery, 104(4), 1221-1230.

Ando, K., Akimoto, K., Sato, H., Manabe, R., Kishino, Y., Homma, T., Kusumoto, S., Yamaoka, T., ... Sagara, H. (2020). Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis. Cancers, 12(4)

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., ... PACIFIC Investigators (2018). Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 379(24), 2342-2350.

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., ... PACIFIC Investigators (2017). Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. New England Journal of Medicine, 377(20), 1919-1929.

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., ... Hellmann, M. D. (2018). Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36(28), 2872-2878.

Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., ... Preiser, J. C. (2017). ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition, 36(1), 11-48.

Arter, Z. L., & Nagasaka, M. (2024). The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact. Lung Cancer (Auckland, N.Z.), 15, 1-8.

Asamura, H., Chansky, K., Crowley, J., Goldstraw, P., Rusch, V. W., Vansteenkiste, J. F., Watanabe, H., Wu, Y. L., ... International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, A. v. B. M. a. P. I. (2015). The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 10(12), 1675-84.

Asciak, R., Bedawi, E. O., Bhatnagar, R., Clive, A. O., Hassan, M., Lloyd, H., Reddy, R., Roberts, H., & Rahman, N. M. (2023). British Thoracic Society Clinical Statement on pleural procedures. Thorax, 78(Suppl 3), s43-s68.

Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., Congedo, M. T., Gomez, D. R., ... Rodrigues, G. B. (2014). An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clinical Lung Cancer, 15(5), 346-55.

Auperin, A., Arriagada, R., Pignon, J. P., Le Pechoux, C., Gregor, A., Stephens, R. J., Kristjansen, P. E., Johnson, B. E., ... Aisner, J. (1999). Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. New England Journal of Medicine, 341(7), 476-84.

Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., ... Pignon, J. P. (2010). Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. Journal of Clinical Oncology, 28(13), 2181-90.

Avasarala, S. K., Lentz, R. J., & Maldonado, F. (2021). Medical Thoracoscopy. Clinics in Chest Medicine, 42(4), 751-766.

Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., Heng, J. C., Dahlberg, S. E., ... Sholl, L. M. (2016). MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. Journal of Clinical Oncology,

Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., ... Giaccone, G. (2009). American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of Clinical Oncology, 27(36), 6251-6266.

Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., ... Zalcman, G. (2021). First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet, 397(10272), 375-386.

Baize, N., Monnet, I., Greillier, L., Geier, M., Lena, H., Janicot, H., Vergnenegre, A., Crequit, J., ... Groupe Français de Pneumo-Cancérologie 01–13 investigators (2020). Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology, 21(9), 1224-1233.

Bankier, A. A., MacMahon, H., Goo, J. M., Rubin, G. D., Schaefer-Prokop, C. M., & Naidich, D. P. (2017). Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society. Radiology, 285(2), 584-600.

Barlesi, F., Vansteenkiste, J., Spigel, D., Ishii, H., Garassino, M., de Marinis, F., Özgüroğlu, M., Szczesna, A., ... Park, K. (2018). Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. The Lancet. Oncology,

Basse, C., Chabanol, H., Bonte, P. E., Fromantin, I., & Girard, N. (2022). Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. Lung Cancer, 173, 116-123.

Baudin, E., Capdevila, J., Hörsch, D., Singh, S., Caplin, M. E., Wolin, E. M., Buikhuisen, W., Raderer, M., ... Reidy-Lagunes, D. (2024). Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study. Endocrine-Related Cancer, 31(9)

Baudin, E., Caplin, M., Garcia-Carbonero, R., Fazio, N., Ferolla, P., Filosso, P. L., Frilling, A., de Herder, W. W., ... ESMO Guidelines Committee (2021). Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(4), 439-451.

Baumann, P., Nyman, J., Hoyer, M., Gagliardi, G., Lax, I., Wennberg, B., Drugge, N., Ekberg, L., ... Lewensohn, R. (2008). Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiotherapy and Oncology, 88(3), 359-67.

Baumann, P., Nyman, J., Hoyer, M., Wennberg, B., Gagliardi, G., Lax, I., Drugge, N., Ekberg, L., ... Lewensohn, R. (2009). Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. Journal of Clinical Oncology, 27(20), 3290-3296.

Belli, C., Anand, S., Gainor, J. F., Penault-Llorca, F., Subbiah, V., Drilon, A., Andrè, F., & Curigliano, G. (2020). Progresses Toward Precision Medicine in  RET-altered Solid Tumors. Clinical Cancer Research, 26(23), 6102-6111.

Berardi, R., De Lisa, M., Pagliaretta, S., Onofri, A., Morgese, F., Savini, A., Ballatore, Z., Caramanti, M., ... Cascinu, S. (2014). Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treatment Reviews, 40(4), 495-506.

Berry, M. F., D'Amico, T. A., Onaitis, M. W., & Kelsey, C. R. (2014). Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. Annals of Thoracic Surgery, 98(1), 197-202.

Besse, B., Lin, J. J., Bazhenova, L., Goto, K., de Langen, A. J., Kim, D. W., Wolf, J., Springfeld, C., ... Solomon, B. J. (2026). Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial. Nature Medicine, 32(2), 682-689.

Bi, N., & Wang, L. (2015). Superiority of concomitant chemoradiation over sequential chemoradiation in inoperable, locally advanced non-small cell lung cancer: challenges in the selection of appropriate chemotherapy. Seminars in Radiation Oncology, 25(2), 122-32.

Bilski, M., Mertowska, P., Mertowski, S., Sawicki, M., Hymos, A., Niedźwiedzka-Rystwej, P., & Grywalska, E. (2021). The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung. Cancers, 14(1)

Bischof, M., Debus, J., Herfarth, K., Muley, T., Kappes, J., Storz, K., & Hoffmann, H. (2007). Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy. Strahlentherapie und Onkologie, 183(12), 679-684.

Bissett, D., Macbeth, F. R., & Cram, I. (1991). The role of palliative radiotherapy in malignant mesothelioma. Clinical Oncology (Royal College of Radiologists), 3(6), 315-7.

Bolliger, C. T., Sutedja, T. G., Strausz, J., & Freitag, L. (2006). Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents. European Respiratory Journal, 27(6), 1258-1271.

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., ... Brahmer, J. R. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373(17), 1627-39.

Bossé, Y., & Amos, C. I. (2018). A Decade of GWAS Results in Lung Cancer. Cancer Epidemiology, Biomarkers and Prevention, 27(4), 363-379.

Bousema, J. E., Dijkgraaf, M. G. W., van der Heijden, E., Verhagen, A., Annema, J. T., van den Broek, F. J. C., & group, M. E. s. (2023). Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial. Journal of Clinical Oncology, 41(22), 3805-3815.

Bradley, J., & Movsas, B. (2004). Radiation esophagitis: Predictive factors and preventive strategies. Seminars in Radiation Oncology, 14(4), 280-6.

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E., Poddubskaya, E., Antonia, S., Pluzanski, A., ... Spigel, D. R. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373(2), 123-35.

Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., ... Ernstoff, M. S. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for immunotherapy of cancer, 9(6)

Brcic, L., & Kern, I. (2020). Clinical significance of histologic subtyping of malignant pleural mesothelioma. Translational lung cancer research, 9(3), 924-933.

Brierley, J. D., Giuliani, M., O’Sullivan, B., Rous, B., Van Eycken, E. (2025). TNM Classification of Malignant Tumours. Wiley.

Brierley, J. D., Gospodarowicz, M. K., Wittekind, C. (2017). TNM Classification of Malignant Tumours. Wiley.

Brokx, H. A. P., Risse, E. K., Paul, M. A., Grunberg, K., Golding, R. P., Kunst, P. W. A., Eerenberg, J., van Mourik, J. C., ... Sutedja, T. G. (2007). Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. Journal of Thoracic and Cardiovascular Surgery, 133(4), 973-978.

Brown, D. J. (2006). Palliation of breathlessness. Clinical medicine, 6(2), 133-6.

Brown, P. D., Ballman, K. V., Cerhan, J. H., Anderson, S. K., Carrero, X. W., Whitton, A. C., Greenspoon, J., Parney, I. F., ... Roberge, D. (2017). Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. The Lancet. Oncology, 18(8), 1049-1060.

Brustugun, O. T., Grønberg, B. H., Fjellbirkeland, L., Helbekkmo, N., Aanerud, M., Grimsrud, T. K., Helland, Å., Møller, B., ... Solberg, S. K. (2018). Substantial nation-wide improvement in lung cancer relative survival in  Norway from 2000 to 2016  . Lung Cancer, 122, 138-145.

Brustugun, O. T., Nilssen, Y., & Eide, I. J. Z. (2021). Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study. Acta Oncologica, 60(10), 1250-1256.

Bugge, A. S., Lund, M. B., Valberg, M., Brustugun, O. T., Solberg, S., & Kongerud, J. (2018). Cause-specific death after surgical resection for early-stage non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery, 53(1), 221-227.

Bunn, P. A., Crowley, J., Kelly, K., Hazuka, M. B., Beasley, K., Upchurch, C., Livingston, R., Weiss, G. R., ... Gandara, D. R. (1995). Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. Journal of Clinical Oncology, 13(7), 1632-41.

Bydder, S., Phillips, M., Joseph, D. J., Cameron, F., Spry, N. A., DeMelker, Y., & Musk, A. W. (2004). A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. British Journal of Cancer, 91(1), 9-10.

Bydder, S., Spry, N. A., Christie, D. R. H., Roos, D., Burmeister, B. H., Krawitz, H., Davis, S., Joseph, D. J., ... Berry, M. (2003). A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. Australasian Radiology, 47(3), 284-288.

Callister, M. E., Baldwin, D. R., Akram, A. R., Barnard, S., Cane, P., Draffan, J., Franks, K., Gleeson, F., ... British Thoracic Society Standards of Care Committee (2015). British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax, 70 Suppl 2, ii1-ii54.

Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & CONSORT PRO Group (2013). Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA, 309(8), 814-22.

Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C., Han, J. Y., Lee, J. S., Hochmair, M. J., Li, J. Y., ... Popat, S. (2018). Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 379(21), 2027-2039.

Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C. H., Han, J. Y., Hochmair, M. J., Lee, K. H., Delmonte, A., ... Popat, S. (2020). Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. Journal of Clinical Oncology, 38(31), 3592-3603.

Cañizares, M. A., Matilla, J. M., Cueto, A., Algar, J., Muguruza, I., Moreno-Mata, N., Moreno-Balsalobre, R., Guijarro, R., ... EMETNE-SEPAR Members (2014). Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. Thorax, 69(7), 648-53.

Cannon, D. M., Mehta, M. P., Adkison, J. B., Khuntia, D., Traynor, A. M., Tomé, W. A., Chappell, R. J., Tolakanahalli, R., ... Cannon, G. M. (2013). Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. Journal of Clinical Oncology, 31(34), 4343-8.

Cao, C. Q., Yan, T. D., Bannon, P. G., & McCaughan, B. C. (2010). A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Thoracic Oncology, 5(10), 1692-703.

Caplin, M. E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., Oberg, K., Pelosi, G., ... ENETS consensus conference participants (2015). Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of Oncology,

Cardillo, G., Sera, F., Di Martino, M., Graziano, P., Giunti, R., Carbone, L., Facciolo, F., & Martelli, M. (2004). Bronchial carcinoid tumors: nodal status and long-term survival after resection. Annals of Thoracic Surgery, 77(5), 1781-5.

Carter, B. W., Benveniste, M. F., Madan, R., Godoy, M. C., de Groot, P. M., Truong, M. T., Rosado-de-Christenson, M. L., & Marom, E. M. (2017). ITMIG Classification of Mediastinal Compartments and Multidisciplinary Approach to Mediastinal Masses. Radiographics, 37(2), 413-436.

Carter, B. W., Benveniste, M. F., Madan, R., Godoy, M. C., Groot, P. M., Truong, M. T., Rosado-de-Christenson, M. L., & Marom, E. M. (2017). IASLC/ITMIG Staging System and Lymph Node Map for Thymic Epithelial Neoplasms. Radiographics, 37(3), 758-776.

Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lu, S., Sepesi, B., Tanaka, F., Taube, J. M., ... Investigators, C. 7. (2024). Perioperative Nivolumab in Resectable Lung Cancer. New England Journal of Medicine, 390(19), 1756-1769.

Castello, A., Rossi, S., & Lopci, E. (2020). 18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art. Current radiopharmaceuticals, 13(3), 228-237.

Cavaliere, S., Venuta, F., Foccoli, P., Toninelli, C., & La Face, B. (1996). Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest, 110(6), 1536-42.

Chakrabarty, N., Mahajan, A., Patil, V., Noronha, V., & Prabhash, K. (2023). Imaging of brain metastasis in non-small-cell lung cancer: indications, protocols, diagnosis, post-therapy imaging, and implications regarding management. Clinical Radiology, 78(3), 175-186.

Chandrasekar, D., Tribett, E., & Ramchandran, K. (2016). Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer. Current Treatment Options in Oncology, 17(5), 23.

Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., Groen, H. J., McRae, S. E., ... Roth, J. A. (2015). Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet. Oncology,

Chapel, D. B., Schulte, J. J., Husain, A. N., & Krausz, T. (2020). Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Translational lung cancer research, 9(Suppl 1), S3-S27.

Chen, G., Huynh, M., Chen, A., Fehrenbacher, L., Gandara, D., & Lau, D. (2008). Chemotherapy for brain metastases in small-cell lung cancer. Clinical Lung Cancer, 9(1), 35-38.

Chen, G., Huynh, M., Fehrenbacher, L., West, H., Lara, P. N., Yavorkovsky, L. L., Russin, M., Goldstein, D., ... Lau, D. (2009). Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. Journal of Clinical Oncology, 27(9), 1401-4.

Chen, L., Shen, C., Redmond, K. J., Page, B. R., Kummerlowe, M., Mcnutt, T., Bettegowda, C., Rigamonti, D., ... Kleinberg, L. (2017). Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics, 98(4), 939-947.

Cheng, S., Evans, W. K., Stys-Norman, D., & Shepherd, F. A. (2007). Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. Journal of Thoracic Oncology, 2(4), 348-354.

Cheng, Y., Spigel, D. R., Cho, B. C., Laktionov, K. K., Fang, J., Chen, Y., Zenke, Y., Lee, K. H., ... Investigators, A. (2024). Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 391(14), 1313-1327.

Cherny, N. I., Catane, R., Kosmidis, P., & ESMO Taskforce on Supportive and Palliative Care (2003). ESMO takes a stand on supportive and palliative care. Annals of Oncology, 14(9), 1335-7.

Chiu, C. H., Chern, M. S., Wu, M. H., Hsu, W. H., Wu, Y. C., Huang, M. H., & Chang, S. C. (2003). Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. Journal of Thoracic and Cardiovascular Surgery, 125(6), 1300-5.

Cho, J., Kim, H. S., Ku, B. M., Choi, Y. L., Cristescu, R., Han, J., Sun, J. M., Lee, S. H., ... Ahn, M. J. (2018). Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Journal of Clinical Oncology, , JCO2017773184.

Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., ... Ahn, M. J. (2020). Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). Journal of Clinical Oncology, 38(5), 488-495.

Christensen, N. L., Jekunen, A., Heinonen, S., Dalton, S. O., & Rasmussen, T. R. (2017). Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison. Acta Oncologica, 56(7), 943-948.

Chung, H. C., Piha-Paul, S. A., Lopez-Martin, J., Schellens, J. H. M., Kao, S., Miller, W. H., Delord, J. P., Gao, B., ... Ott, P. A. (2020). Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. Journal of Thoracic Oncology, 15(4), 618-627.

Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., Johannsdottir, H. K., Klughammer, B., & Gonzalez, E. E. (2012). Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. The Lancet. Oncology, 13(3), 300-8.

Colt, H. G., Murgu, S. D., Korst, R. J., Slatore, C. G., Unger, M., & Quadrelli, S. (2013). Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e437S-54S.

Crona, J., Fanola, I., Lindholm, D. P., Antonodimitrakis, P., Öberg, K., Eriksson, B., & Granberg, D. (2013). Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology, 98(2), 151-5.

Cuffe, S., Booth, C. M., Peng, Y., Darling, G. E., Li, G., Kong, W., Mackillop, W. J., & Shepherd, F. A. (2012). Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada. Journal of Clinical Oncology, 30(15), 1813-21.

Dagogo-Jack, I., Moonsamy, P., Gainor, J. F., Lennerz, J. K., Piotrowska, Z., Lin, J. J., Lennes, I. T., Sequist, L. V., ... Heist, R. S. (2021). A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. Journal of Thoracic Oncology, 16(5), 850-859.

Dam, G., Grønbæk, H., Sundlöv, A., Botling, J., Sundin, A., Petersen, R. H., Welin, S., Evensen, E. T., ... Langer, S. W. (2023). Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. Acta Oncologica, 62(5), 431-437.

Damirov, F., Büsing, K., Yavuz, G., Hatz, R., Manapov, F., Michels, J., Hohenberger, P., & Roessner, E. (2023). Preoperative Hilar and Mediastinal Lymph Node Staging in Patients with Suspected or Diagnosed Lung Cancer: Accuracy of 18F-FDG-PET/CT:A Retrospective Cohort Study of 138 Patients. Diagnostics (Basel), 13(3)

Damirov, F., Stoleriu, M. G., Manapov, F., Büsing, K., Michels, J. D., Preissler, G., Hatz, R. A., Hohenberger, P., & Roessner, E. D. (2023). Histology of the Primary Tumor Correlates with False Positivity of Integrated 18F-FDG-PET/CT Lymph Node Staging in Resectable Lung Cancer Patients. Diagnostics (Basel), 13(11)

de Alencar, V. T. L., Formiga, M. N., & de Lima, V. C. C. (2020). Inherited lung cancer: a review. Ecancermedicalscience, 14, 1008.

de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., Lammers, J. J., Weenink, C., ... Oudkerk, M. (2020). Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. New England Journal of Medicine, 382(6), 503-513.

De Leyn, P., Dooms, C., Kuzdzal, J., Lardinois, D., Passlick, B., Rami-Porta, R., Turna, A., Van Schil, P., ... Zielinski, M. (2014). Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery, 45(5), 787-98.

de Perrot, M., Feld, R., Cho, B. C., Bezjak, A., Anraku, M., Burkes, R., Roberts, H., Tsao, M. S., ... Johnston, M. R. (2009). Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. Journal of Clinical Oncology, 27(9), 1413-8.

De Ruysscher, D., Botterweck, A., Dirx, M., Pijls-Johannesma, M., Wanders, R., Hochstenbag, M., Dingemans, A. M., Bootsma, G., ... Lambin, P. (2009). Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Annals of Oncology, 20(1), 98-102.

De Ruysscher, D., Nakagawa, K., & Asamura, H. (2014). Surgical and nonsurgical approaches to small-size nonsmall cell lung cancer. European Respiratory Journal, 44(2), 483-94.

De Ruysscher, D., & Slotman, B. (2003). Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey. Radiotherapy and Oncology, 68(3), 299-302.

Desai, R., Koipallil, G. K., Thomas, N., Mhaskar, R., Visweshwar, N., Laber, D., Patel, A., & Jaglal, M. (2020). Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. Scientific Reports, 10(1), 18945.

Detterbeck, F. C. (2010). Management of carcinoid tumors. Annals of Thoracic Surgery, 89(3), 998-1005.

Detterbeck, F. C., Nicholson, A. G., Franklin, W. A., Marom, E. M., Travis, W. D., Girard, N., Arenberg, D. A., Bolejack, V., ... Participating Institutions (2016). The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal of Thoracic Oncology, 11(5), 639-650.

Detterbeck, F. C., Nicholson, A. G., Kondo, K., Van Schil, P., & Moran, C. (2011). The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. Journal of Thoracic Oncology, 6(7 Suppl 3), S1710-6.

Dingemans, A. C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L. E., Lantuejoul, S., Peters, S., ... clinicalguidelines@esmo.org, E. G. C. E. a. (2021). Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(7), 839-853.

Dingemans, A. C., Hendriks, L. E. L., Berghmans, T., Levy, A., Hasan, B., Faivre-Finn, C., Giaj-Levra, M., Giaj-Levra, N., ... Novello, S. (2019). Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. Journal of Thoracic Oncology, 14(12), 2109-2119.

Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., ... trial investigators (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet. Oncology, 21(2), 271-282.

Doebele, R. C., Perez, L., Trinh, H., Martinec, M., Martina, R., Riehl, T., Krebs, M. G., Meropol, N. J., ... Crane, G. (2021). Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in. Journal of comparative effectiveness research, 10(17), 1271-1282.

Dominioni, L., Rotolo, N., Mantovani, W., Poli, A., Pisani, S., Conti, V., Paolucci, M., Sessa, F., ... Imperatori, A. (2012). A population-based cohort study of chest x-ray screening in smokers: lung cancer detection findings and follow-up. BMC Cancer, 12, 18.

Drilon, A., Camidge, D. R., Lin, J. J., Kim, S. W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., ... Investigators, T. (2024). Repotrectinib in ROS1 Fusion–Positive  Non–Small-Cell Lung Cancer. New England Journal of Medicine, 390(2), 118-131.

Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., ... Subbiah, V. (2020). Efficacy of Selpercatinib in in RET Fusion-Positive Non-Small-Cell Lung Cancer.. New England Journal of Medicine, 383(9), 813-824.

Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., de Braud, F., Rolfo, C., ... trial investigators (2020). Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. The Lancet. Oncology, 21(2), 261-270.

Drilon, A., Siena, S., Ou, S. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., ... De Braud, F. G. (2017). Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery, 7(4), 400-409.

Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., de Braud, F., Solomon, B. J., Shao-Weng Tan, D., Alonso, G., ... Besse, B. (2023). Selpercatinib in Patients With RET fusion–positive non–small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial.. Journal of Clinical Oncology, 41(2), 385-394.

Dunne, E. G., Fick, C. N., & Jones, D. R. (2023). Mediastinal Staging in Non-Small-Cell Lung Cancer: Saying Goodbye to Mediastinoscopy. Journal of Clinical Oncology, 41(22), 3785-3790.

Dziadziuszko, R., Krebs, M. G., De Braud, F., Siena, S., Drilon, A., Doebele, R. C., Patel, M. R., Cho, B. C., ... Barlesi, F. (2021). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic. Journal of Clinical Oncology, 39(11), 1253-1263.

Eblan, M. J., Corradetti, M. N., Lukens, J. N., Xanthopoulos, E., Mitra, N., Christodouleas, J. P., Grover, S., Fernandes, A. T., ... Apisarnthanarax, S. (2013). Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications. International Journal of Radiation Oncology, Biology, Physics, 85(1), 175-81.

Edvardsen, E., Skjønsberg, O. H., Holme, I., Nordsletten, L., Borchsenius, F., & Anderssen, S. A. (2015). High-intensity training following lung cancer surgery: a randomised controlled trial. Thorax, 70(3), 244-50.

Eguren-Santamaria, I., Sanmamed, M. F., Goldberg, S. B., Kluger, H. M., Idoate, M. A., Lu, B. Y., Corral, J., Schalper, K. A., ... Gil-Bazo, I. (2020). PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research, 26(16), 4186-4197.

Eide, I. J. Z., Stensgaard, S., Helland, Å., Ekman, S., Mellemgaard, A., Hansen, K. H., Cicenas, S., Koivunen, J., ... Brustugun, O. T. (2022). Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials. Translational lung cancer research, 11(6), 953-963.

El Zarif, T., Nassar, A. H., Adib, E., Fitzgerald, B. G., Huang, J., Mouhieddine, T. H., Rubinstein, P. G., Nonato, T., ... Naqash, A. R. (2023). Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. Journal of Clinical Oncology, 41(21), 3712-3723.

Ellis, P., Davies, A. M., Evans, W. K., Haynes, A. E., Lloyd, N. S., & Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care (2006). The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. Journal of Thoracic Oncology, 1(6), 591-601.

El-Sherief, A. H., Lau, C. T., Carter, B. W., & Wu, C. C. (2018). Staging Lung Cancer: Regional Lymph Node Classification. Radiologic Clinics of North America, 56(3), 399-409.

Ernst, A., Feller-Kopman, D., Becker, H. D., & Mehta, A. C. (2004). Central airway obstruction. American Journal of Respiratory and Critical Care Medicine, 169(12), 1278-1297.

Eze, C., Käsmann, L., & Manapov, F. (2019). Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer. JAMA oncology, 5(1), 11-12.

Fairchild, A., Harris, K., Barnes, E., Wong, R., Lutz, S., Bezjak, A., Cheung, P., & Chow, E. (2008). Palliative thoracic radiotherapy for lung cancer: a systematic review. Journal of Clinical Oncology, 26(24), 4001-4011.

Faivre-Finn, C., Snee, M., Ashcroft, L., Appel, W., Barlesi, F., Bhatnagar, A., Bezjak, A., Cardenal, F., ... Team, C. S. (2017). Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. The Lancet. Oncology, 18(8), 1116-1125.

Falcoz, P. E., Puyraveau, M., Thomas, P. A., Decaluwe, H., Hürtgen, M., Petersen, R. H., Hansen, H., Brunelli, A., & ESTS Database Committee and ESTS Minimally Invasive Interest Group (2015). Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. European Journal of Cardio-Thoracic Surgery,

Falk, S. J., Girling, D. J., White, R. J., Hopwood, P., Harvey, A., Qian, W., & Stephens, R. J. (2002). Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ, 325(7362), 465-465.

Falkson, C. B., Bezjak, A., Darling, G., Gregg, R., Malthaner, R., Maziak, D. E., Yu, E., Smith, C. A., ... Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care (2009). The management of thymoma: a systematic review and practice guideline. Journal of Thoracic Oncology, 4(7), 911-9.

Falkson, C. B., Vella, E. T., Ellis, P. M., Maziak, D. E., Ung, Y. C., & Yu, E. (2022). Surgical, Radiation, and Systemic Treatments of Patients with Thymic Epithelial Tumours: A Clinical Practice Guideline. Journal of Thoracic Oncology,

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., ... POPLAR Study Group (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387(10030), 1837-46.

Felip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., ... IMpower010 Investigators (2021). Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet,

Felip, E., Rosell, R., Maestre, J. A., Rodríguez-Paniagua, J. M., Morán, T., Astudillo, J., Alonso, G., Borro, J. M., ... Group, S. L. C. (2010). Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. Journal of Clinical Oncology, 28(19), 3138-45.

Felip, E., Shaw, A. T., Bearz, A., Camidge, D. R., Solomon, B. J., Bauman, J. R., Bauer, T. M., Peters, S., ... Besse, B. (2021). Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Annals of Oncology, 32(5), 620-630.

Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, R., Hanna, G. G., Hill, K., Danson, S., Steele, N., ... CONFIRM trial investigators (2021). Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. The Lancet. Oncology, 22(11), 1530-1540.

Ferguson, M. K., & Lehman, A. G. (2003). Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Annals of Thoracic Surgery, 76(6), 1782-1788.

Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer,

Fernandez-Cuesta, L., Peifer, M., Lu, X., Sun, R., Seidel, D., Zander, T., Leenders, F., George, J., ... Thomas, R. K. (2014). Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nature communications, 5, 3518.

Ferrara, M. G., Stefani, A., Simbolo, M., Pilotto, S., Martini, M., Lococo, F., Vita, E., Chiappetta, M., ... Bria, E. (2021). Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. Frontiers in Oncology, 11, 650293.

Ferris, F. D., Bruera, E., Cherny, N., Cummings, C., Currow, D., Dudgeon, D., Janjan, N., Strasser, F., ... Von Roenn, J. H. (2009). Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. Journal of Clinical Oncology, 27(18), 3052-8.

Filosso, P. L., Oliaro, A., Ruffini, E., Bora, G., Lyberis, P., Asioli, S., Delsedime, L., Sandri, A., & Guerrera, F. (2013). Outcome and prognostic factors in bronchial carcinoids: a single-center experience. Journal of Thoracic Oncology, 8(10), 1282-8.

Filosso, P. L., Yao, X., Ruffini, E., Ahmad, U., Antonicelli, A., Huang, J., Guerrera, F., Venuta, F., ... Korst, R. (2016). Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group. European Journal of Cardio-Thoracic Surgery, 50(4), 766-771.

Fink, G., Krelbaum, T., Yellin, A., Bendayan, D., Saute, M., Glazer, M., & Kramer, M. R. (2001). Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest, 119(6), 1647-51.

Fogh, S., & Yom, S. S. (2014). Symptom management during the radiation oncology treatment course: a practical guide for the oncology clinician. Seminars in Oncology, 41(6), 764-75.

Folch, E. E., Labarca, G., Ospina-Delgado, D., Kheir, F., Majid, A., Khandhar, S. J., Mehta, H. J., Jantz, M. A., & Fernandez-Bussy, S. (2020). Sensitivity and Safety of Electromagnetic Navigation Bronchoscopy for Lung Cancer Diagnosis: Systematic Review and Meta-analysis. Chest, 158(4), 1753-1769.

Forde, P. M., Spicer, J., & Girard, N. (2022). Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply. New England Journal of Medicine, 387(6), 572-573.

Forde, P. M., Spicer, J. D., Provencio, M., Mitsudomi, T., Awad, M. M., Wang, C., Lu, S., Felip, E., ... Investigators, C. 8. (2025). Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. New England Journal of Medicine, 393(8), 741-752.

Foster, C. C., Rusthoven, C. G., Sher, D. J., Feldman, L., Pasquinelli, M., Spiotto, M. T., & Koshy, M. (2019). Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis. Lung Cancer, 130, 162-168.

Francis, S., Orton, A., Stoddard, G., Tao, R., Hitchcock, Y. J., Akerley, W., & Kokeny, K. E. (2017). Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, , JCO2017744771.

Früh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., Felip, E., & ESMO Guidelines Working Group (2013). Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24 Suppl 6, vi99-105.

Fujii, Y. (2011). Published guidelines for management of thymoma. Thoracic Surgery Clinics, 21(1), 125-9, viii.

Gadgeel, S. M., Shaw, A. T., Govindan, R., Gandhi, L., Socinski, M. A., Camidge, D. R., De Petris, L., Kim, D. W., ... Ou, S. I. (2016). Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 34(34), 4079-4085.

Gaebe, K., Erickson, A. W., Li, A. Y., Youssef, A. N., Sharma, B., Chan, K. K. W., Lok, B. H., & Das, S. (2024). Re-examining prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis. EClinicalMedicine, 67, 102396.

Gainor, J. F., Curigliano, G., Kim, D. W., Lee, D. H., Besse, B., Baik, C. S., Doebele, R. C., Cassier, P. A., ... Subbiah, V. (2021). Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. The Lancet. Oncology, 22(7), 959-969.

Gandhi, L., & Garassino, M. C. (2018). Pembrolizumab plus Chemotherapy in Lung Cancer. New England Journal of Medicine, 379(11), e18.

Garassino, M. C., Gadgeel, S., Speranza, G., Felip, E., Esteban, E., Dómine, M., Hochmair, M. J., Powell, S. F., ... Rodríguez-Abreu, D. (2023). Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. Journal of Clinical Oncology, 41(11), 1992-1998.

Garassino, M. C., Mazieres, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., Cove-Smith, L., Mansy, T., ... Faivre-Finn, C. (2022). Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. Journal of Thoracic Oncology,

Garon, E. B., Ciuleanu, T. E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., ... Pérol, M. (2014). Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet, 384(9944), 665-73.

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., ... KEYNOTE-001 Investigators (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. New England Journal of Medicine, 372(21), 2018-28.

Genova, C., Rijavec, E., & Grossi, F. (2016). Hematopoietic growth factors in lung cancer. Current Opinion in Oncology, 28(2), 135-44.

George, J., Walter, V., Peifer, M., Alexandrov, L. B., Seidel, D., Leenders, F., Maas, L., Müller, C., ... Thomas, R. K. (2018). Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nature communications, 9(1), 1048.

George, R., Jeba, J., Ramkumar, G., Chacko, A. G., & Tharyan, P. (2015). Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database of Systematic Reviews, (9), CD006716.

Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Powderly, J., Heist, R., ... Brahmer, J. (2018). Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. Journal of Clinical Oncology, 36(17), 1675-1684.

Gibson, A. J. W., Pabani, A., Dean, M. L., Martos, G., Cheung, W. Y., & Navani, V. (2023). Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in. JTO clinical and research reports, 4(3), 100460.

Gillespie, C. S., Mustafa, M. A., Richardson, G. E., Alam, A. M., Lee, K. S., Hughes, D. M., Escriu, C., & Zakaria, R. (2023). Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology, 18(12), 1703-1713.

Girard, N., Ruffini, E., Marx, A., Faivre-Finn, C., Peters, S., & ESMO Guidelines Committee (2015). Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26 Suppl 5, v40-55.

Gogishvili, M., Melkadze, T., Makharadze, T., Giorgadze, D., Dvorkin, M., Penkov, K., Laktionov, K., Nemsadze, G., ... Rietschel, P. (2022). Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nature Medicine, 28(11), 2374-2380.

Gollard, R., Jhatakia, S., Elliott, M., & Kosty, M. (2010). Large cell/neuroendocrine carcinoma. Lung Cancer, 69(1), 13-8.

Gomes, F., Faivre-Finn, C., Mistry, H., Bezjak, A., Pourel, N., Fournel, P., Van Meerbeeck, J., & Blackhall, F. (2021). Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. Lung Cancer, 153, 165-170.

Gomez, D. R., Tang, C., Zhang, J., Blumenschein, G. R., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., ... Heymach, J. V. (2019). Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology, 37(18), 1558-1565.

Gorenberg, M., Bar-Shalom, R., & Israel, O. (2008). Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. British Journal of Radiology, 81(970), 821-5.

Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S. W., Planchard, D., Ahn, M. J., Smit, E. F., ... Jänne, P. A. (2023). Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. Journal of Clinical Oncology, 41(31), 4852-4863.

Gould, M. K., Donington, J., Lynch, W. R., Mazzone, P. J., Midthun, D. E., Naidich, D. P., & Wiener, R. S. (2013). Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e93S-120S.

Graabak, G., Grønberg, B. H., Sandvei, M. S., Nilssen, Y., & Halvorsen, T. O. (2022). Thoracic Radiotherapy in Limited-Stage SCLC-a Population-Based Study of Patterns of Care in Norway From 2000 Until 2018. JTO clinical and research reports, 3(2), 100270.

Grassi, L., Nanni, M. G., Rodin, G., Li, M., & Caruso, R. (2018). The use of antidepressants in oncology: a review and practical tips for oncologists. Annals of Oncology, 29(1), 101-111.

Gridelli, C., Ardizzoni, A., Ciardiello, F., Hanna, N., Heymach, J. V., Perrone, F., Rosell, R., Shepherd, F. A., ... De Marinis, F. (2008). Second-line treatment of advanced non-small cell lung cancer. Journal of Thoracic Oncology, 3(4), 430-440.

Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C. S., Tan, D. S. W., Lee, D. H., Misch, D., ... Mazières, J. (2022). Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Annals of Oncology, 33(11), 1168-1178.

Grosso, F., Cerbone, L., & Curioni-Fontecedro, A. (2024). MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma. The Lancet. Respiratory medicine, 12(6), 423-424.

Grønberg, B. H., Halvorsen, T. O., Fløtten, Ø., Brustugun, O. T., Brunsvig, P. F., Aasebø, U., Bremnes, R. M., Tollåli, T., ... Norwegian Lung Cancer Study Group (2016). Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncologica, 55(5), 591-7.

Grønberg, B. H., Killingberg, K. T., Fløtten, Ø., Brustugun, O. T., Hornslien, K., Madebo, T., Langer, S. W., Schytte, T., ... Halvorsen, T. O. (2021). High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. The Lancet. Oncology, 22(3), 321-331.

Grøndahl, V., Binderup, T., Langer, S. W., Petersen, R. H., Nielsen, K., Kjaer, A., Federspiel, B., & Knigge, U. (2019). Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence. Lung Cancer, 132, 141-149.

Guckenberger, M., Mantel, F., Gerszten, P. C., Flickinger, J. C., Sahgal, A., Létourneau, D., Grills, I. S., Jawad, M., ... Kersh, R. (2014). Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiation oncology, 9, 226.

Guisier, F., Dubos-Arvis, C., Viñas, F., Doubre, H., Ricordel, C., Ropert, S., Janicot, H., Bernardi, M., ... Bylicki, O. (2020). Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. Journal of Thoracic Oncology, 15(4), 628-636.

Gulstene, S., Ruwanpura, T., Palma, D., & Joseph, N. (2022). Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer - A Done Deal?. Clinical Oncology (Royal College of Radiologists), 34(11), 733-740.

Ha, D., Mazzone, P. J., Ries, A. L., Malhotra, A., & Fuster, M. (2016). The Utility of Exercise Testing in Patients with Lung Cancer. Journal of Thoracic Oncology, 11(9), 1397-410.

Haldorsen, T., Andersen, A., & Boffetta, P. (2004). Smoking-adjusted incidence of lung cancer by occupation among Norwegian men. Cancer Causes and Control, 15(2), 139-47.

Hallifax, R. J., Talwar, A., Wrightson, J. M., Edey, A., & Gleeson, F. V. (2017). State-of-the-art: Radiological investigation of pleural disease. Respiratory Medicine, 124, 88-99.

Hamaji, M., Kojima, F., Omasa, M., Sozu, T., Sato, T., Chen, F., Sonobe, M., & Date, H. (2015). A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma. European Journal of Cardio-Thoracic Surgery, 47(4), 602-7.

Hansell, D. M., Bankier, A. A., MacMahon, H., McLoud, T. C., Müller, N. L., & Remy, J. (2008). Fleischner Society: glossary of terms for thoracic imaging. Radiology, 246(3), 697-722.

Harkenrider, M. M., Bertke, M. H., & Dunlap, N. E. (2014). Stereotactic body radiation therapy for unbiopsied early-stage lung cancer: a multi-institutional analysis. American Journal of Clinical Oncology, 37(4), 337-42.

Harpole, D. H., Feldman, J. M., Buchanan, S., Young, W. G., & Wolfe, W. G. (1992). Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Annals of Thoracic Surgery, 54(1), 50-4; discussion 54-5.

Hassan, R., Morrow, B., Thomas, A., Walsh, T., Lee, M. K., Gulsuner, S., Gadiraju, M., Panou, V., ... Churpek, J. E. (2019). Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 116(18), 9008-9013.

Helbekkmo, N., Sundstrom, S. H., Aasebo, U., Brunsvig, P. F., von Plessen, C., Hjelde, H. H., Garpestad, O. K., Bailey, A., & Bremnes, R. M. (2007). Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. British Journal of Cancer, 97(3), 283-9.

Helland, Å., Solberg, S., & Brustugun, O. T. (2012). Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases. Journal of Thoracic Oncology, 7(12), 1858-61.

Hendriks, L. E., Hermans, B. C., van den Beuken-van Everdingen, M. H., Hochstenbag, M. M., & Dingemans, A. M. (2016). Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review. Journal of Thoracic Oncology, 11(2), 155-73.

Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., ... clinicalguidelines@esmo.org, E. G. C. E. a. (2023). Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(4), 358-376.

Herbst, R. S., Baas, P., Kim, D. W., Felip, E., Pérez-Gracia, J. L., Han, J. Y., Molina, J., Kim, J. H., ... Garon, E. B. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 387(10027), 1540-50.

Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., ... Spigel, D. R. (2020). Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. New England Journal of Medicine, 383(14), 1328-1339.

Herbst, R. S., Wu, Y. L., John, T., Grohe, C., Majem, M., Wang, J., Kato, T., Goldman, J. W., ... Tsuboi, M. (2023). Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of Clinical Oncology, 41(10), 1830-1840.

Herder, G. J., van Tinteren, H., Golding, R. P., Kostense, P. J., Comans, E. F., Smit, E. F., & Hoekstra, O. S. (2005). Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest, 128(4), 2490-6.

Heymach, J. V., Harpole, D., Mitsudomi, T., Taube, J. M., Galffy, G., Hochmair, M., Winder, T., Zukov, R., ... Investigators, A. (2023). Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. New England Journal of Medicine, 389(18), 1672-1684.

Heymach, J. V., Ruiter, G., Ahn, M. J., Girard, N., Smit, E. F., Planchard, D., Wu, Y. L., Cho, B. C., ... Investigators, B. L. (2025). Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine,

Hishida, T., Nagai, K., Yoshida, J., Nishimura, M., Ishii, G., Iwasaki, M., & Nishiwaki, Y. (2006). Is surgical resection indicated for a solitary non-small cell lung cancer recurrence?. Journal of Thoracic and Cardiovascular Surgery, 131(4), 838-842.

Hochmair, M., Weinlinger, C., Schwab, S., Naber, J., Setinek, U., Krenbek, D., Urban, M. H., Fabikan, H., ... Burghuber, O. C. (2019). Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. Anti-Cancer Drugs, 30(7), e0787.

Hollevoet, K., Reitsma, J. B., Creaney, J., Grigoriu, B. D., Robinson, B. W., Scherpereel, A., Cristaudo, A., Pass, H. I., ... van Meerbeeck, J. P. (2012). Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. Journal of Clinical Oncology, 30(13), 1541-9.

Holsti, L. R., Pyrhonen, S., Kajanti, M., Mantyla, M., Mattson, K., Maasilta, P., & Kivisaari, L. (1997). Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncologica, 36(4), 397-405.

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., ... Drilon, A. (2020). Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. The Lancet. Oncology, 21(4), 531-540.

Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., ... IMpower133 Study Group (2018). First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 379(23), 2220-2229.

Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004). Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 22(19), 3852-3859.

Huang, J., Detterbeck, F. C., Wang, Z., & Loehrer, P. J. (2011). Standard outcome measures for thymic malignancies. Journal of Thoracic Oncology, 6(7 Suppl 3), S1691-7.

Huber, R. M., Hansen, K. H., Paz-Ares Rodríguez, L., West, H. L., Reckamp, K. L., Leighl, N. B., Tiseo, M., Smit, E. F., ... Camidge, D. R. (2020). Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology, 15(3), 404-415.

Hui, D., & Bruera, E. (2016). Integrating palliative care into the trajectory of cancer care. Nature reviews. Clinical oncology, 13(3), 159-71.

Huo, Y. R., Chan, M. V., Habib, A. R., Lui, I., & Ridley, L. (2020). Pneumothorax rates in CT-Guided lung biopsies: a comprehensive systematic review and meta-analysis of risk factors. British Journal of Radiology, 93(1108), 20190866.

IARC (2021). Thoracic tumours (5 utg.) (WHO Classification of Tumours). Lyon: International Agency for Research on Cancer.

Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., ... Timmerman, R. D. (2018). Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA oncology, 4(1), e173501.

Iyoda, A., Hiroshima, K., Moriya, Y., Iwadate, Y., Takiguchi, Y., Uno, T., Nakatani, Y., & Yoshino, I. (2009). Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. Journal of Thoracic and Cardiovascular Surgery, 138(2), 446-53.

Jakopovic, M., Bitar, L., Seiwerth, F., Marusic, A., Krpina, K., & Samarzija, M. (2020). Immunotherapy for thymoma. Journal of Thoracic Disease, 12(12), 7635-7641.

Jänne, P. A., Planchard, D., Kobayashi, K., Yang, J. C., Liu, Y., Valdiviezo, N., Kim, T. M., Jiang, L., ... Investigators, F. (2025). Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine,

Jasper, K., Stiles, B., McDonald, F., & Palma, D. A. (2022). Practical Management of Oligometastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40(6), 635-641.

Jennings, A. L., Davies, A. N., Higgins, J. P., Gibbs, J. S., & Broadley, K. E. (2002). A systematic review of the use of opioids in the management of dyspnoea. Thorax, 57(11), 939-44.

Jensen, L. H., Osterlind, K., & Rytter, C. (2008). Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer, 62(1), 85-91.

Johnson, D. B., Chandra, S., & Sosman, J. A. (2018). Immune Checkpoint Inhibitor Toxicity in 2018. JAMA, 320(16), 1702-1703.

Johnson, M. L., De Langen, J., Waterhouse, D. M., Mazieres, J., Dingemans, A. C., Mountzios, G., Pless, M., Wolf, J., ... Paz-Ares, L. (2022). Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Annals of Oncology, 33, S808-S869.

Johnson, P. T., Horton, K. M., & Fishman, E. K. (2009). Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics, 29(5), 1333-51.

Kaasa, S., Loge, J. H., Aapro, M., Albreht, T., Anderson, R., Bruera, E., Brunelli, C., Caraceni, A., ... Lundeby, T. (2018). Integration of oncology and palliative care: a Lancet Oncology Commission. The Lancet. Oncology, 19(11), e588-e653.

Kadota, K., Suzuki, K., Colovos, C., Sima, C. S., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2012). A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Modern Pathology, 25(2), 260-71.

Kandathil, A., Kay, F. U., Butt, Y. M., Wachsmann, J. W., & Subramaniam, R. M. (2018). Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. Radiographics, 38(7), 2134-2149.

Kandathil, A., & Subramaniam, R. M. (2022). FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma. Seminars in Nuclear Medicine, 52(6), 650-661.

Kann, B. H., Miccio, J. A., Stahl, J. M., Ross, R., Verma, V., Dosoretz, A. P., Park, H. S., Shafman, T. D., ... Decker, R. H. (2019). Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiotherapy and Oncology, 132, 188-196.

Kantor, T., & Wakeam, E. (2021). Landmark Trials in the Surgical Management of Mesothelioma. Annals of Surgical Oncology,

Kauczor, H. U., Bonomo, L., Gaga, M., Nackaerts, K., Peled, N., Prokop, M., Remy-Jardin, M., von Stackelberg, O., ... European Respiratory Society (ERS) (2015). ESR/ERS white paper on lung cancer screening. European Respiratory Journal, 46(1), 28-39.

Kelly, R. J., Sharon, E., & Hassan, R. (2011). Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer, 73(3), 256-63.

Kenmotsu, H., Yamamoto, N., Yamanaka, T., Yoshiya, K., Takahashi, T., Ueno, T., Goto, K., Daga, H., ... Tsuboi, M. (2020). Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38(19), 2187-2196.

Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. (2019). Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. Journal of the National Comprehensive Cancer Network, 17(6), 750-757.

Kidane, B., Bott, M., Spicer, J., Backhus, L., Chaft, J., Chudgar, N., Colson, Y., D'Amico, T. A., ... Stiles, B. (2023). The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 166(3), 637-654.

Kim, D. W., Tiseo, M., Ahn, M. J., Reckamp, K. L., Hansen, K. H., Kim, S. W., Huber, R. M., West, H. L., ... Camidge, D. R. (2017). Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 35(22), 2490-2498.

Kim, M., Suh, C. H., Lee, S. M., Kim, H. C., Aizer, A. A., Yanagihara, T. K., Bai, H. X., Guenette, J. P., ... Kim, H. S. (2020). Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non-Small Cell Lung Cancer. Radiology, 297(2), 419-427.

Kodama, K., Doi, O., Higashiyama, M., & Yokouchi, H. (1997). Intentional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: a single-institution study. Journal of Thoracic and Cardiovascular Surgery, 114(3), 347-353.

Komaki, R., & Gomez, D. R. (2014). Radiotherapy for Thymic Carcinoma: Adjuvant, Inductive, and Definitive. Frontiers in Oncology, 3, 330.

Komiya, T., Ravindra, N., & Powell, E. (2021). Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung. Asian Pacific Journal of Cancer Prevention, 22(2), 365-370.

Korse, C. M., Taal, B. G., Vincent, A., van Velthuysen, M. L., Baas, P., Buning-Kager, J. C., Linders, T. C., & Bonfrer, J. M. (2012). Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. European Journal of Cancer, 48(5), 662-71.

Korst, R. J., Bezjak, A., Blackmon, S., Choi, N., Fidias, P., Liu, G., Marx, A., Wright, C., ... Keshavjee, S. (2014). Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. Journal of Thoracic and Cardiovascular Surgery, 147(1), 36-44, 46.e1.

Kozower, B. D., Larner, J. M., Detterbeck, F. C., & Jones, D. R. (2013). Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e369S-e399S.

Kreuter, M., Vansteenkiste, J., Fischer, J. R., Eberhardt, W., Zabeck, H., Kollmeier, J., Serke, M., Frickhofen, N., ... TREAT investigators (2013). Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Annals of Oncology, 24(4), 986-92.

Krug, L. M., Pass, H. I., Rusch, V. W., Kindler, H. L., Sugarbaker, D. J., Rosenzweig, K. E., Flores, R., Friedberg, J. S., ... Vogelzang, N. J. (2009). Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. Journal of Clinical Oncology, 27(18), 3007-13.

Kulke, M. H., Lenz, H. J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., Bergsland, E., Stuart, K., ... Fuchs, C. S. (2008). Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 26(20), 3403-10.

Kumar, A., Weber, M. H., Gokaslan, Z., Wolinsky, J. P., Schmidt, M., Rhines, L., Fehlings, M. G., Laufer, I., ... Fisher, C. G. (2017). Metastatic Spinal Cord Compression and Steroid Treatment: A Systematic Review. Clinical spine surgery, 30(4), 156-163.

Lakha, S., Gomez, J. E., Flores, R. M., & Wisnivesky, J. P. (2014). Prognostic significance of visceral pleural involvement in early-stage lung cancer. Chest, 146(6), 1619-1626.

Lamba, N., Muskens, I. S., DiRisio, A. C., Meijer, L., Briceno, V., Edrees, H., Aslam, B., Minhas, S., ... Broekman, M. L. (2017). Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. Radiation oncology, 12(1), 106.

Larici, A. R., Franchi, P., Del Ciello, A., Sica, G., Coviello, D., De Waure, C., Cicchetti, G., Rovere, G., ... Manfredi, R. (2021). Role of delayed phase contrast-enhanced CT in the intra-thoracic staging of non-small cell lung cancer (NSCLC): What does it add?. European Journal of Radiology, 144, 109983.

Le Péchoux, C., Dunant, A., Senan, S., Wolfson, A., Quoix, E., Faivre-Finn, C., Ciuleanu, T., Arriagada, R., ... Prophylactic Cranial Irradiation (PCI) Collaborative Group (2009). Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. The Lancet. Oncology, 10(5), 467-74.

Le Péchoux, C., Laplanche, A., Faivre-Finn, C., Ciuleanu, T., Wanders, R., Lerouge, D., Keus, R., Hatton, M., ... Prophylactic Cranial Irradiation (PCI) Collaborative Group (2011). Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Annals of Oncology, 22(5), 1154-63.

Le Pechoux, C., Pourel, N., Barlesi, F., Lerouge, D., Antoni, D., Lamezec, B., Nestle, U., Boisselier, P., ... Bardet, A. (2022). Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. The Lancet. Oncology, 23(1), 104-114.

Le Treut, J., Sault, M. C., Lena, H., Souquet, P. J., Vergnenegre, A., Le Caer, H., Berard, H., Boffa, S., ... Chouaid, C. (2013). Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Annals of Oncology, 24(6), 1548-52.

Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., ... Investigators, S. (2025). Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. New England Journal of Medicine, 393(18), 1819-1832.

Lee, S. M., Schulz, C., Prabhash, K., Kowalski, D., Szczesna, A., Han, B., Rittmeyer, A., Talbot, T., ... Peters, S. (2023). First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. Lancet, 402(10400), 451-463.

Lee, T. H., Marcantonio, E. R., Mangione, C. M., Thomas, E. J., Polanczyk, C. A., Cook, E. F., Sugarbaker, D. J., Donaldson, M. C., ... Goldman, L. (1999). Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation, 100(10), 1043-9.

Lemaire, A., Nikolic, I., Petersen, T., Haney, J. C., Toloza, E. M., Harpole, D. H. ,. J., D'Amico, T. A., & Burfeind, W. R. (2006). Nine-year single center experience with cervical mediastinoscopy: complications and false negative rate. Annals of Thoracic Surgery, 82(4), 1185-9; discussion 1189-90.

Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., Azimi, R., Rizvi, H., ... Awad, M. M. (2018). Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. Journal of Clinical Oncology, 36(19), 1905-1912.

Leong, T. L., Loveland, P. M., Gorelik, A., Irving, L., & Steinfort, D. P. (2019). Preoperative Staging by EBUS in cN0/N1 Lung Cancer: Systematic Review and Meta-Analysis. Journal of bronchology & interventional pulmonology, 26(3), 155-165.

Li, A., Garcia, D. A., Lyman, G. H., & Carrier, M. (2019). Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thrombosis Research, 173, 158-163.

Li, X., & Kong, L. (2023). Ultrasound versus computed tomography-guided transthoracic biopsy for pleural and peripheral lung lesions: a systematic review and meta-analysis. Acta Radiologica, 64(12), 2999-3008.

Li, Y., Chen, W., Xie, F., Huang, R., Liu, X., Xiao, Y., Cao, L., Hu, Y., ... Sun, J. (2023). Novel electromagnetic navigation bronchoscopy system for the diagnosis of peripheral pulmonary nodules: a prospective, multicentre study. Thorax, 78(12), 1197-1205.

Li, Y., Yang, F., Huang, Y. Y., & Cao, W. (2022). Comparison between computed tomography-guided core and fine needle lung biopsy: A meta-analysis. Medicine (Baltimore), 101(9), e29016.

Liao, X., Liu, M., Li, S., Huang, W., Guo, C., Liu, J., Xiong, Y., Zhang, J., ... Wang, R. (2023). The value on SUV-derived parameters assessed on (18)F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer. BMC Medical Imaging, 23(1), 49.

Liao, Z., Lee, J. J., Komaki, R., Gomez, D. R., O'Reilly, M. S., Fossella, F. V., Blumenschein, G. R., Heymach, J. V., ... Mohan, R. (2018). Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36(18), 1813-1822.

Lim, E., Baldwin, D., Beckles, M., Duffy, J., Entwisle, J., Faivre-Finn, C., Kerr, K., Macfie, A., ... Society for Cardiothoracic Surgery in Great Britain and Ireland (2010). Guidelines on the radical management of patients with lung cancer. Thorax, 65 Suppl 3, iii1-27.

Lim, E., Waller, D., Lau, K., Steele, J., Pope, A., Ali, C., Bilancia, R., Keni, M., ... Investigators, M. 2. (2024). Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. The Lancet. Respiratory medicine, 12(6), 457-466.

Lim, S. M., Kim, H. R., Lee, J. S., Lee, K. H., Lee, Y. G., Min, Y. J., Cho, E. K., Lee, S. S., ... Cho, B. C. (2017). Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. Journal of Clinical Oncology, 35(23), 2613-2618.

Limonnik, V., Abel, S., Finley, G. G., Long, G. S., & Wegner, R. E. (2020). Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis. Lung Cancer, 150, 107-113.

Lindberg, K., Grozman, V., Karlsson, K., Lindberg, S., Lax, I., Wersäll, P., Persson, G. F., Josipovic, M., ... Lewensohn, R. (2021). The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. Journal of Thoracic Oncology, 16(7), 1200-1210.

Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., ... Garon, E. B. (2018). A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. Journal of Thoracic Oncology, 13(8), 1138-1145.

Lock, M. I., Hoyer, M., Bydder, S. A., Okunieff, P., Hahn, C. A., Vichare, A., & Dawson, L. A. (2012). An international survey on liver metastases radiotherapy. Acta Oncologica, 51(5), 568-74.

Lococo, F., Guerrera, F., Rena, O., Ampollini, L., Vannucci, J., Bertoglio, P., Ventura, L., Lyberis, P., ... Ruffini, E. (2022). Accuracy of (18)F-FDG in Detecting Stage I Lung Adenocarcinomas According to IASLC/ATS/ERS Classification. Heart, Lung & Circulation, 31(5), 726-732.

Loehrer, P. J., Wang, W., Johnson, D. H., Aisner, S. C., Ettinger, D. S., & Eastern Cooperative Oncology Group Phase II Trial (2004). Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. Journal of Clinical Oncology, 22(2), 293-9.

Lou, F., Huang, J., Sima, C. S., Dycoco, J., Rusch, V., & Bach, P. B. (2013). Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. Journal of Thoracic and Cardiovascular Surgery, 145(1), 75-81; discussion 81-2.

Lou, F., Sarkaria, I., Pietanza, C., Travis, W., Roh, M. S., Sica, G., Healy, D., Rusch, V., & Huang, J. (2013). Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. Annals of Thoracic Surgery, 96(4), 1156-1162.

Loulergue, P., Alexandre, J., Iurisci, I., Grabar, S., Medioni, J., Ropert, S., Dieras, V., Le Chevalier, F., ... Launay, O. (2011). Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study. British Journal of Cancer, 104(11), 1670-4.

Louw, A., Panou, V., Szejniuk, W. M., Meristoudis, C., Chai, S. M., van Vliet, C., Lee, Y. C. G., Dick, I. M., ... Røe, O. D. (2022). BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. Journal of Thoracic Oncology, 17(7), 921-930.

Lu, S., Ahn, M. J., Reungwetwattana, T., Özgüroğlu, M., Kato, T., Yang, J. C., Huang, M., Fujiki, F., ... Ramalingam, S. S. (2024). Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study. Annals of Oncology, 35(12), 1116-1125.

Lu, S., Kato, T., Dong, X., Ahn, M. J., Quang, L. V., Soparattanapaisarn, N., Inoue, T., Wang, C. L., ... Investigators, L. T. (2024). Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. New England Journal of Medicine,

Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Ma, Z., Li, X., He, W., ... Wang, M. (2024). Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial). ESMO Open, 9(10), 103728.

Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Wangjun, L., Li, X., Liu, Y., ... Wang, M. (2025). . Oncology and therapy, 13(4), 1087-1104.

Lund-Iversen, M., Grøholt, K. K., Helland, Å., Borgen, E., & Brustugun, O. T. (2015). NUT expression in primary lung tumours. Diagnostic Pathology, 10, 156.

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., ... Haber, D. A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129-39.

Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., ... Group, E. S. D. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 43(41), 4229-4361.

Mackley, H. B., & Videtic, G. M. (2006). Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park, N.Y.), 20(12), 1537-43; discussion 1544-5, 1549.

MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., Mehta, A. C., Ohno, Y., ... Bankier, A. A. (2017). Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology, 284(1), 228-243.

Makharadze, T., Gogishvili, M., Melkadze, T., Baramidze, A., Giorgadze, D., Penkov, K., Laktionov, K., Nemsadze, G., ... Rietschel, P. (2023). Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. Journal of Thoracic Oncology, 18(6), 755-768.

Manohar, S., Thongprayoon, C., Cheungpasitporn, W., Markovic, S. N., & Herrmann, S. M. (2020). Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. Kidney international reports, 5(2), 149-158.

Mao, J., Kocak, Z., Zhou, S., Garst, J., Evans, E. S., Zhang, J., Larrier, N. A., Hollis, D. R., ... Marks, L. B. (2007). The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. International Journal of Radiation Oncology, Biology, Physics, 67(5), 1360-9.

Marinaccio, A., Binazzi, A., Cauzillo, G., Cavone, D., Zotti, R. D., Ferrante, P., Gennaro, V., Gorini, G., ... Tumino, R. (2007). Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. European Journal of Cancer, 43(18), 2722-8.

Marom, E. M. (2013). Advances in thymoma imaging. Journal of Thoracic Imaging, 28(2), 69-80; quiz 81-3.

Martinez-Zayas, G., Molina, S., & Ost, D. E. (2022). Sensitivity and complications of thoracentesis and thoracoscopy: a meta-analysis. European respiratory review, 31(166)

Martinou, M., & Gaya, A. (2013). Cardiac complications after radical radiotherapy. Seminars in Oncology, 40(2), 178-85.

Marx, A., Chan, J. K. C., Chalabreysse, L., Dacic, S., Detterbeck, F., French, C. A., Hornick, J. L., Inagaki, H., ... Ströbel, P. (2022). The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. Journal of Thoracic Oncology, 17(2), 200-213.

Masaoka, A. (2010). Staging system of thymoma. Journal of Thoracic Oncology, 5(10 Suppl 4), S304-12.

Massoth, L. R., Hung, Y. P., Dias-Santagata, D., Onozato, M., Shah, N., Severson, E., Duncan, D., Gillespie, B. J., ... Williams, E. A. (2020). Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A- MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma. JCO precision oncology, 4

Matheos, T., Ram, L., & Canelli, R. (2020). Preoperative Evaluation for Thoracic Surgery. Thoracic Surgery Clinics, 30(3), 241-247.

Matsumoto, R., Takamori, S., Yokoyama, S., Hashiguchi, T., Murakami, D., Yoshiyama, K., Nishi, T., Kashihara, M., ... Akagi, Y. (2018). Lung function in the late postoperative phase and influencing factors in patients undergoing pulmonary lobectomy. Journal of Thoracic Disease, 10(5), 2916-2923.

Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., ... Gautschi, O. (2013). Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. Journal of Clinical Oncology, 31(16), 1997-2003.

McKenna, R. J., Mahtabifard, A., Yap, J., McKenna, R., Fuller, C., Merhadi, A., & Hakimian, B. (2008). Wedge resection and brachytherapy for lung cancer in patients with poor pulmonary function. Annals of Thoracic Surgery, 85(2), 733-736.

Mehta, V. (2005). Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. International Journal of Radiation Oncology, Biology, Physics, 63(1), 5-24.

Mesko, S., & Gomez, D. (2018). Proton Therapy in Non-small Cell Lung Cancer. Current Treatment Options in Oncology, 19(12), 76.

Moertel, C. G., & Hanley, J. A. (1979). Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clinical Trials, 2(4), 327-34.

Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., Sunpaweravong, P., Han, B., ... Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947-57.

Mok, T. S. K., Wu, Y. L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., ... KEYNOTE-042 Investigators (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 393(10183), 1819-1830.

Mollberg, N. M., & Ferguson, M. K. (2013). Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Annals of Thoracic Surgery, 95(3), 1112-21.

Mulvenna, P., Nankivell, M., Barton, R., Faivre-Finn, C., Wilson, P., McColl, E., Moore, B., Brisbane, I., ... Langley, R. E. (2016). Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet, 388(10055), 2004-2014.

Mynarek, G. K., & Bosse, G. (2016). Re: Behandling av gassembolier. Tidsskrift for den Norske Legeforening, 136(16), 1323-4.

Naidoo, J., Santos-Zabala, M. L., Iyriboz, T., Woo, K. M., Sima, C. S., Fiore, J. J., Kris, M. G., Riely, G. J., ... Pietanza, M. C. (2016). Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer, 17(5), e121-e129.

Nakamura, K., Matsumoto, K., Inoue, C., Matsusue, E., & Fujii, S. (2021). Computed Tomography-guided Lung Biopsy: A Review of Techniques for Reducing the Incidence of Complications. Interventional radiology (Higashimatsuyama-shi (Japan), 6(3), 83-92.

Nantavithya, C., Gomez, D. R., Wei, X., Komaki, R., Liao, Z., Lin, S. H., Jeter, M., Nguyen, Q. N., ... Chang, J. Y. (2018). Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 101(3), 558-563.

Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F., Xu, C., Kaldas, D., Gray, J. E., ... Goldberg, S. B. (2024). Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal of Thoracic Oncology, 19(6), 928-940.

Neyman, K., Sundset, A., Naalsund, A., Espinoza, A., Solberg, S., Kongerud, J., & Fosse, E. (2012). Endoscopic treatment of bronchial carcinoids in comparison to surgical resection: a retrospective study. Journal of bronchology & interventional pulmonology, 19(1), 29-34.

Nezu, K., Kushibe, K., Tojo, T., Takahama, M., & Kitamura, S. (1998). Recovery and limitation of exercise capacity after lung resection for lung cancer. Chest, 113(6), 1511-1516.

Ng, T. L., Narasimhan, N., Gupta, N., Venkatakrishnan, K., Kerstein, D., & Camidge, D. R. (2020). Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. Journal of Thoracic Oncology, 15(7), 1190-1199.

Nguyen, Q. N., Chun, S. G., Chow, E., Komaki, R., Liao, Z., Zacharia, R., Szeto, B. K., Welsh, J. W., ... Lewis, V. O. (2019). Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA oncology,

Nilssen, Y., Brustugun, O. T., Fjellbirkeland, L., Grønberg, B. H., Haram, P. M., Helbekkmo, N., Helland, Å., Wahl, S. G. F., ... Solberg, S. (2024). Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends. Clinical Lung Cancer, 25(5), e221-e228.e3.

Non-small Cell Lung Cancer Collaborative Group (1995). Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ, 311(7010), 899-909.

Noonan, C. W. (2017). Environmental asbestos exposure and risk of mesothelioma. Annals of translational medicine, 5(11), 234.

Nussbaum, D. P., Speicher, P. J., Gulack, B. C., Hartwig, M. G., Onaitis, M. W., D'Amico, T. A., & Berry, M. F. (2015). Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. Annals of Thoracic Surgery, 99(2), 428-34.

O'Brien, M. E., Ciuleanu, T. E., Tsekov, H., Shparyk, Y., Cuceviá, B., Juhasz, G., Thatcher, N., Ross, G. A., ... Crofts, T. (2006). Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. Journal of Clinical Oncology, 24(34), 5441-7.

O'Brien, M. E., Watkins, D., Ryan, C., Priest, K., Corbishley, C., Norton, A., Ashley, S., Rowell, N., & Sayer, R. (2006). A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Annals of Oncology, 17(2), 270-5.

O'Rourke, N., Garcia, J. C., Paul, J., Lawless, C., McMenemin, R., & Hill, J. (2007). A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiotherapy and Oncology, 84(1), 18-22.

Oken, M. M., Hocking, W. G., Kvale, P. A., Andriole, G. L., Buys, S. S., Church, T. R., Crawford, E. D., Fouad, M. N., ... PLCO Project Team (2011). Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA, 306(17), 1865-73.

Ostios-Garcia, L., Faig, J., Leonardi, G. C., Adeni, A. E., Subegdjo, S. J., Lydon, C. A., Rangachari, D., Huberman, M. S., ... Awad, M. M. (2018). Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 13(7), 1037-1042.

Ou, S. H., Ahn, J. S., De Petris, L., Govindan, R., Yang, J. C., Hughes, B., Lena, H., Moro-Sibilot, D., ... Kim, D. W. (2016). Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Journal of Clinical Oncology, 34(7), 661-8.

Ou, S. I., Nishio, M., Ahn, M. J., Mok, T., Barlesi, F., Zhou, C., Felip, E., de Marinis, F., ... Kim, E. S. (2022). Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology,

Owens, C., Hindocha, S., Lee, R., Millard, T., & Sharma, B. (2023). The lung cancers: staging and response, CT, (18)F-FDG PET/CT, MRI, DWI: review and new perspectives. British Journal of Radiology, 96(1148), 20220339.

Özgüroğlu, M., Kilickap, S., Sezer, A., Gümüş, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., ... Rietschel, P. (2023). First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 24(9), 989-1001.

Özmen, Ö., ... Öztürk, A. (2021). Contribution of (18)F-FDG PET/CT in the Differential Diagnosis of Pulmonary Hamartomas and Pulmonary Carcinoids. Molecular imaging and radionuclide therapy, 30(2), 101-106.

Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., West, R. B., & Wakelee, H. A. (2015). Diffuse high intensity PD-L1 staining in thymic epithelial tumors. Journal of Thoracic Oncology, 10(3), 500-8.

Page, S., Milner-Watts, C., Perna, M., Janzic, U., Vidal, N., Kaudeer, N., Ahmed, M., McDonald, F., ... O'Brien, M. (2020). Systemic treatment of brain metastases in non-small cell lung cancer. European Journal of Cancer, 132, 187-198.

Paik, P. K., Iams, W. T., Husain, H., O'Hara, R. M. ,. J., Adewusi, E., & Le, X. (2025). Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer. Cancer Treatment Reviews, 139, 102990.

Palussière, J., Cazayus, M., Cousin, S., Cabart, M., Chomy, F., Catena, V., & Buy, X. (2021). Is There a Role for Percutaneous Ablation for Early Stage Lung Cancer? What Is the Evidence?. Current Oncology Reports, 23(7), 81.

Pancoast, H. (1932). Superior pulmonary sulcus tumor. JAMA, 99, 1391-6.

Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J. Y., ... Cho, B. C. (2021). Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 39(30), 3391-3402.

Passaro, A., Wang, J., Wang, Y., Lee, S. H., Melosky, B., Shih, J. Y., Azuma, K., Juan-Vidal, O., ... Investigators, M. (2024). Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Annals of Oncology, 35(1), 77-90.

Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., Mohiuddin, M., & Young, B. (2005). Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet, 366(9486), 643-8.

Patel, A., Roshkovan, L., McNulty, S., Alley, E., Torigian, D. A., Nachiappan, A. C., Galperin-Aizenberg, M., Barbosa, E. M., ... Katz, S. I. (2021). Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study. Clinical Lung Cancer, 22(3), 210-217.e1.

Patel, N. V., Yu, N. Y., Koroulakis, A., Diwanji, T., Sawant, A., Sio, T. T., & Mohindra, P. (2021). Proton therapy for thoracic malignancies: a review of oncologic outcomes. Expert Review of Anticancer Therapy, 21(2), 177-191.

Patel, S. H., Robbins, J. R., Gore, E. M., Bradley, J. D., Gaspar, L. E., Germano, I., Ghafoori, P., Henderson, M. A., ... Expert Panel on Radiation Oncology–Brain Metastases (2012). ACR Appropriateness Criteria® follow-up and retreatment of brain metastases. American Journal of Clinical Oncology, 35(3), 302-6.

Payne, C., Larkin, P. J., McIlfatrick, S., Dunwoody, L., & Gracey, J. H. (2013). Exercise and nutrition interventions in advanced lung cancer: a systematic review. Current oncology, 20(4), e321-37.

Paz-Ares, L., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., ... Goldman, J. W. (2022). Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open, 7(2), 100408.

Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., ... CASPIAN investigators (2019). Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, 394(10212), 1929-1939.

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., ... KEYNOTE-407 Investigators (2018). Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 379(21), 2040-2051.

Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., ... Halmos, B. (2020). A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology, 15(10), 1657-1669.

Pedersen, J. H., Sørensen, J. B., Saghir, Z., Fløtten, Ø., Brustugun, O. T., Ashraf, H., Strand, T. E., Friesland, S., ... Gudbjartsson, T. (2017). Implementation of lung cancer CT screening in the Nordic countries. Acta Oncologica, 56(10), 1249-1257.

Pelayo Alvarez, M., Gallego Rubio, O., Bonfill Cosp, X., & Agra Varela, Y. (2009). Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews, (4), CD001990.

Pencharz, D., Modi, S., Bandyopadhyay, S., Alhun, U., Marchbank, N., Patel, A., & Wagner, T. (2022). Absence of clinical benefit of FDG PET-CT in staging T1 part-solid lung adenocarcinoma. Clinical Radiology, 77(3), 195-202.

Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D. W., Ou, S. I., Pérol, M., ... ALEX Trial Investigators (2017). Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine,

Pignon, J. P., Tribodet, H., Scagliotti, G. V., Douillard, J. Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., ... Group, L. C. (2008). Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology, 26(21), 3552-9.

Pijls-Johannesma, M. C. G., De Ruysscher, D., Lambin, P., Rutten, I., & Vansteenkiste, J. F. (2005). Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database of Systematic Reviews, (1)

Planchard, D., Besse, B., Groen, H. J., Souquet, P. J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., ... Johnson, B. E. (2016). Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. The Lancet. Oncology, 17(7), 984-93.

Planchard, D., Besse, B., Groen, H. J. M., Hashemi, S. M. S., Mazieres, J., Kim, T. M., Quoix, E., Souquet, P. J., ... Johnson, B. E. (2022). Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. Journal of Thoracic Oncology, 17(1), 103-115.

Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C., Yanagitani, N., Kim, S. W., Sugawara, S., Yu, Y., ... Investigators, F. (2023). Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 389(21), 1935-1948.

Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., ... Johnson, B. E. (2017). Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. The Lancet. Oncology, 18(10), 1307-1316.

Polanski, J., Jankowska-Polanska, B., Rosinczuk, J., Chabowski, M., & Szymanska-Chabowska, A. (2016). Quality of life of patients with lung cancer. OncoTargets and Therapy, 9, 1023-8.

Popat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., Fisher, P., Spicer, J., ... Stahel, R. A. (2020). A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Annals of Oncology, 31(12), 1734-1745.

Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., Peters, S., & ESMO Guidelines Committee (2017). Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 28(suppl_4), iv1-iv21.

Prelaj, A., Pircher, C. C., Massa, G., Martelli, V., Corrao, G., Lo Russo, G., Proto, C., Ferrara, R., ... Rebuzzi, S. E. (2021). Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers, 13(6)

Prosperi, D., Carideo, L., Russo, V. M., Meucci, R., Campagna, G., Lastoria, S., & Signore, A. (2023). A Systematic Review on Combined [(18)F]FDG and (68)Ga-SSA PET/CT in Pulmonary Carcinoid. Journal of Clinical Medicine Research, 12(11)

Pujol, J. L., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Uwer, L., Hureaux, J., Guisier, F., Carmier, D., ... Souquet, P. J. (2019). A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. Journal of Thoracic Oncology, 14(5), 903-913.

Radovich, M., Pickering, C. R., Felau, I., Ha, G., Zhang, H., Jo, H., Hoadley, K. A., Anur, P., ... Cancer Genome Atlas Network (2018). The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell, 33(2), 244-258.e10.

Rajan, A., Carter, C. A., Berman, A., Cao, L., Kelly, R. J., Thomas, A., Khozin, S., Chavez, A. L., ... Giaccone, G. (2014). Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. The Lancet. Oncology, 15(2), 191-200.

Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., ... FLAURA Investigators (2020). Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 382(1), 41-50.

Raman, V., Jawitz, O. K., Yang, C. J., Tong, B. C., D'Amico, T. A., Berry, M. F., & Harpole, D. H. (2019). Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis. Annals of Thoracic Surgery, 108(2), 377-383.

Raman, V., Jawitz, O. K., Yang, C. J., Voigt, S. L., Tong, B. C., D'Amico, T. A., & Harpole, D. H. (2019). Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer. Journal of Thoracic Oncology, 14(12), 2143-2151.

Rami-Porta, R., Nishimura, K. K., Giroux, D. J., Detterbeck, F., Cardillo, G., Edwards, J. G., Fong, K. M., Giuliani, M., ... Members of the IASLC Staging and Prognostic Factors Committee and of the Advisory Boards, a. P. I. (2024). The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 19(7), 1007-1027.

Rath, J., Mauritz, M., Zulehner, G., Hilger, E., Cetin, H., Kasprian, G., Auff, E., & Zimprich, F. (2017). Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study. Journal of Neurology, 264(6), 1209-1217.

Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K. M., Peters, S., & ESMO Guidelines Working Group (2014). Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 25 Suppl 3, iii27-39.

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., ... KEYNOTE-024 Investigators (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 375(19), 1823-1833.

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., ... BO17704 Study Group (2010). Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology, 21(9), 1804-9.

Refai, M., Brunelli, A., Salati, M., Pompili, C., Xiumè, F., & Sabbatini, A. (2011). Efficacy of anterior fissureless technique for right upper lobectomies: a case-matched analysis. European Journal of Cardio-Thoracic Surgery, 39(6), 1043-6.

Rekhtman, N. (2010). Neuroendocrine tumors of the lung: an update. Archives of Pathology and Laboratory Medicine, 134(11), 1628-38.

Rekhtman, N., Desmeules, P., Litvak, A. M., Pietanza, M. C., Santos-Zabala, M. L., Ni, A., Montecalvo, J., Chang, J. C., ... Lai, W. C. (2019). Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. Modern Pathology, 32(8), 1106-1122.

Reveiz, L., Rueda, J. R., & Cardona, A. F. (2012). Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews, 12, CD004284.

Rheinheimer, S., Heussel, C. P., Mayer, P., Gaissmaier, L., Bozorgmehr, F., Winter, H., Herth, F. J., Muley, T., ... Christopoulos, P. (2020). Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers, 12(4)

Ricciuti, B., Dahlberg, S. E., Adeni, A., Sholl, L. M., Nishino, M., & Awad, M. M. (2019). Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. Journal of Clinical Oncology, , JCO1900189.

Rieber, J., Schmitt, J., Warth, A., Muley, T., Kappes, J., Eichhorn, F., Hoffmann, H., Heussel, C. P., ... Rieken, S. (2015). Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. European Journal of Medical Research, 20, 64.

Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., ... OAK Study Group (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 389(10066), 255-265.

Rivera, M. P., Mehta, A. C., & Wahidi, M. M. (2013). Establishing the Diagnosis of Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143(5 Suppl), e142S-65S.

Rogasch, J. M. M., Frost, N., Bluemel, S., Michaels, L., Penzkofer, T., von Laffert, M., Temmesfeld-Wollbrück, B., Neudecker, J., ... Furth, C. (2021). FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. Lung Cancer, 157, 66-74.

Rogasch, J. M. M., Hofheinz, F., van Heek, L., Voltin, C. A., Boellaard, R., & Kobe, C. (2022). Influences on PET Quantification and Interpretation. Diagnostics (Basel), 12(2)

Romi, F. (2011). Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Diseases, 2011, 474512.

Romi, F., Skeie, G. O., Aarli, J. A., & Gilhus, N. E. (2000). Muscle autoantibodies in subgroups of myasthenia gravis patients. Journal of Neurology, 247(5), 369-75.

Ropper, A. E., & Ropper, A. H. (2017). Acute Spinal Cord Compression. New England Journal of Medicine, 376(14), 1358-1369.

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., ... Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology, 13(3), 239-46.

Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., De Souza, P., ... Seaman, J. (2004). Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer, 100(12), 2613-21.

Rosen, L. S., Gordon, D., Tchekmedyian, S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., ... Seaman, J. J. (2003). Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Journal of Clinical Oncology, 21(16), 3150-7.

Rossi, G., Cavazza, A., Marchioni, A., Longo, L., Migaldi, M., Sartori, G., Bigiani, N., Schirosi, L., ... Brambilla, E. (2005). Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. Journal of Clinical Oncology, 23(34), 8774-85.

Rousseau, B., Loulergue, P., Mir, O., Krivine, A., Kotti, S., Viel, E., Simon, T., de Gramont, A., ... Tournigand, C. (2012). Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Annals of Oncology, 23(2), 450-7.

Rowell, N. P., & Gleeson, F. V. (2001). Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database of Systematic Reviews, (4), CD001316.

Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., ... Infectious Diseases Society of America (2014). 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clinical Infectious Diseases, 58(3), e44-100.

Rubins, J., Unger, M., Colice, G. L., & American College of Chest Physicians (2007). Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest, 132(3 Suppl), 355S-367S.

Rudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Cheema, P. K., Rodriguez-Abreu, D., Wollner, M., ... KEYNOTE-604 Investigators (2020). Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. Journal of Clinical Oncology, 38(21), 2369-2379.

Rudin, C. M., Ismaila, N., Hann, C. L., Malhotra, N., Movsas, B., Norris, K., Pietanza, M. C., Ramalingam, S. S., ... Giaccone, G. (2015). Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. Journal of Clinical Oncology, 33(34), 4106-11.

Ruffini, E., Detterbeck, F., Van Raemdonck, D., Rocco, G., Thomas, P., Weder, W., Brunelli, A., Guerrera, F., ... Venuta, F. (2014). Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database. Journal of Thoracic Oncology, 9, 541–548.

Rusch, V. W., Chansky, K., Kindler, H. L., Nowak, A. K., Pass, H. I., Rice, D. C., Shemanski, L., Galateau-Sallé, F., ... IASLC Staging and Prognostic Factors Committee, ,. a. b. a. p. i. (2016). The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology, 11(12), 2112-2119.

Rusch, V. W., Giroux, D. J., Kraut, M. J., Crowley, J., Hazuka, M., Winton, T., Johnson, D. H., Shulman, L., ... Gandara, D. (2007). Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). Journal of Clinical Oncology, 25(3), 313-8.

Rusthoven, C. G., Yamamoto, M., Bernhardt, D., Smith, D. E., Gao, D., Serizawa, T., Yomo, S., Aiyama, H., ... Robin, T. P. (2020). Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study. JAMA oncology, 6(7), 1028-1037.

Sabari, J. K., Leonardi, G. C., Shu, C. A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., ... Drilon, A. (2018). PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Annals of Oncology, 29(10), 2085-2091.

Sadikov, E., Bezjak, A., Yi, Q. L., Wells, W., Dawson, L., Millar, B. A., & Laperriere, N. (2007). Value of whole brain re-irradiation for brain metastases--single centre experience. Clinical Oncology (Royal College of Radiologists), 19(7), 532-8.

Sagerup, C. M., Småstuen, M., Johannesen, T. B., Helland, Å., & Brustugun, O. T. (2011). Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax, 66(4), 301-7.

Saghir, Z., Dirksen, A., Ashraf, H., Bach, K. S., Brodersen, J., Clementsen, P. F., Døssing, M., Hansen, H., ... Pedersen, J. H. (2012). CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax, 67(4), 296-301.

Saji, H., Tsuboi, M., Matsubayashi, J., Miyajima, K., Shimada, Y., Imai, K., Kato, Y., Usuda, J., ... Ikeda, N. (2010). Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anti-Cancer Drugs, 21(1), 89-93.

Salati, M., & Brunelli, A. (2016). Risk Stratification in Lung Resection. Current surgery reports, 4(11), 37.

Salazar, M. C., Rosen, J. E., Wang, Z., Arnold, B. N., Thomas, D. C., Herbst, R. S., Kim, A. W., Detterbeck, F. C., ... Boffa, D. J. (2017). Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA oncology, 3(5), 610-619.

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, 355(24), 2542-2550.

Santoro, A., O'Brien, M. E., Stahel, R. A., Nackaerts, K., Baas, P., Karthaus, M., Eberhardt, W., Paz-Ares, L., ... Manegold, C. (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. Journal of Thoracic Oncology, 3(7), 756-63.

Saunders, Y., Ross, J. R., Broadley, K. E., Edmonds, P. M., & Patel, S. (2004). Systematic review of bisphosphonates for hypercalcaemia of malignancy. Palliative Medicine, 18(5), 418-431.

Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., Dienemann, H., Galateau-Salle, F., ... European Respiratory Society/European Society of Thoracic Surgeons Task Force (2010). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Journal, 35(3), 479-95.

Schild, S. E., Sio, T. T., Daniels, T. B., Chun, S. G., & Rades, D. (2017). Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer. Journal of Oncology Practice, 13(11), 732-738.

Schindewolf, M., & Weitz, J. I. (2020). Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Thrombosis and Haemostasis, 120(1), 14-26.

Schmidt-Hansen, M., Baldwin, D. R., & Hasler, E. (2012). What is the most effective follow-up model for lung cancer patients? A systematic review. Journal of Thoracic Oncology, 7(5), 821-4.

Schneider, B. J., Ismaila, N., Aerts, J., Chiles, C., Daly, M. E., Detterbeck, F. C., Hearn, J. W. D., Katz, S. I., ... Altorki, N. (2020). Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. Journal of Clinical Oncology, 38(7), 753-766.

Schneider, J. (2006). Tumor markers in detection of lung cancer. Advances in Clinical Chemistry, 42, 1-41.

Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., Kris, M. G., Riely, G. J., ... Hellmann, M. D. (2019). Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Annals of Oncology, 30(5), 839-844.

Schoenmaekers, J. J. A. O., Dingemans, A. C., & Hendriks, L. E. L. (2018). Brain imaging in early stage non-small cell lung cancer: still a controversial topic?. Journal of Thoracic Disease, 10(Suppl 18), S2168-S2171.

Schreiber, D., Rineer, J., Weedon, J., Vongtama, D., Wortham, A., Kim, A., Han, P., Choi, K., & Rotman, M. (2010). Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?. Cancer, 116(5), 1350-7.

Schreuder, A., Jacobs, C., Scholten, E. T., van Ginneken, B., Schaefer-Prokop, C. M., & Prokop, M. (2020). Typical CT Features of Intrapulmonary Lymph Nodes: A Review. Radiol Cardiothorac Imaging, 2(4), e190159.

Schultheiss, T. E. (2008). The radiation dose-response of the human spinal cord. International Journal of Radiation Oncology, Biology, Physics, 71(5), 1455-9.

Schwartz, L. H., Gandras, E. J., Colangelo, S. M., Ercolani, M. C., & Panicek, D. M. (1999). Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology, 210(1), 71-4.

Scognamiglio, A., Zappi, A., Andrini, E., Di Odoardo, A., Campana, D., La Salvia, A., & Lamberti, G. (2025). Updates on Pulmonary Neuroendocrine Carcinoids: Progress and Perspectives. Journal of Clinical Medicine Research, 14(16)

Sechi, E., & Zekeridou, A. (2021). Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. Journal of Thoracic Oncology, 16(3), 381-394.

Seol, H. Y., Kim, Y. S., & Kim, S. J. (2021). Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer. Oncology, 99(2), 96-104.

Sequist, L. V., Yang, J. C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., ... Schuler, M. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology, 31(27), 3327-34.

Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., ... Rietschel, P. (2021). Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet, 397(10274), 592-604.

Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., ... study investigators (2016). Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. The Lancet. Oncology, 17(2), 234-242.

Shaw, A. T., Ou, S. H., Bang, Y. J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., ... Iafrate, A. J. (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. New England Journal of Medicine, 371(21), 1963-71.

Shaw, A. T., Solomon, B. J., Besse, B., Bauer, T. M., Lin, C. C., Soo, R. A., Riely, G. J., Ou, S. I., ... Martini, J. F. (2019). Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 37(16), 1370-1379.

Shaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., Kao, S., Lin, C. C., ... Ou, S. I. (2019). Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. The Lancet. Oncology,

Shaw, P., & Agarwal, R. (2004). Pleurodesis for malignant pleural effusions. Cochrane Database of Systematic Reviews, (1)

Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., Levitan, N., Gressot, L., ... Berille, J. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncology, 18(10), 2095-2103.

Silva, S. C., Wilson, C., & Woll, P. J. (2015). Bone-targeted agents in the treatment of lung cancer. Therapeutic Advances in Medical Oncology, 7(4), 219-28.

Silvestri, G. A., Gonzalez, A. V., Jantz, M. A., Margolis, M. L., Gould, M. K., Tanoue, L. T., Harris, L. J., & Detterbeck, F. C. (2013). Methods for Staging Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143(5 Suppl), e211S-50S.

Simon, G. R., Turrisi, A., & American College of Chest Physicians (2007). Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 324S-339S.

Simone, C. B. (2017). Thoracic Radiation Normal Tissue Injury. Seminars in Radiation Oncology, 27(4), 370-377.

Singh, D., Chen, Y., Cummings, M. A., & Milano, M. T. (2019). Inoperable Pulmonary Carcinoid Tumors: Local Control Rates With Stereotactic Body Radiotherapy/Hypofractionated RT With Image-Guided Radiotherapy. Clinical Lung Cancer, 20(3), e284-e290.

Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., ... Govindan, R. (2021). Sotorasib for Lung Cancers with KRAS p.G12C Mutations. New England Journal of Medicine, 384(25), 2371-2381.

Skov, B. G., & Skov, T. (2017). Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Applied Immunohistochemistry & Molecular Morphology, 25(7), 453-459.

Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M., Keijser, A., Faivre-Finn, C., & Senan, S. (2015). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet, 385(9962), 36-42.

Smilowitz, N. R., & Berger, J. S. (2020). Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review. JAMA, 324(3), 279-290.

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., ... IMpower150 Study Group (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 378(24), 2288-2301.

Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., ... Shaw, A. T. (2018). Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. The Lancet. Oncology, 19(12), 1654-1667.

Solomon, B. J., Liu, G., Felip, E., Mok, T. S. K., Soo, R. A., Mazieres, J., Shaw, A. T., de Marinis, F., ... Bauer, T. M. (2024). Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of Clinical Oncology, , JCO2400581.

Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., ... PROFILE 1014 Investigators (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New England Journal of Medicine, 371(23), 2167-77.

Sonobe, M., Yamada, T., Sato, M., Menju, T., Aoyama, A., Sato, T., Chen, F., Omasa, M., ... Date, H. (2014). Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Annals of Surgical Oncology, 21(8), 2546-54.

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., ... FLAURA Investigators (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378, 113-125.

Soria, J. C., Tan, D. S., Chiari, R., Wu, Y. L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., ... de Castro, G. (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, 389(10072), 917-929.

Spicer, J. D., Garassino, M. C., Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S. H., Chen, K. N., ... Investigators, K. (2024). Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 404(10459), 1240-1252.

Spigel, D., McLeod, M., Hussein, M., Waterhouse, D., Einhorn, L., Horn, L., Creelan, B., Babu, S., ... Jotte, R. (2017). Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of Oncology, 28, v460-v496.

Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., ... Antonia, S. J. (2022). Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40(12), 1301-1311.

Spigel, D. R., Vicente, D., Ciuleanu, T. E., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo Aranda, N., ... Reck, M. (2021). Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Annals of Oncology, 32(5), 631-641.

Spira, A. I., Paz-Ares, L., Han, J. Y., Shih, J. Y., Mascaux, C., Roy, U. B., Zugazagoitia, J., Kim, Y. J., ... Lopes, G. (2025). Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report. Journal of Thoracic Oncology, 20(6), 809-816.

Spiro, S. G. (2012). Screening for lung cancer: we still need to know more. Thorax, 67(4), 283-5.

Stahel, R. A., Weder, W., Lievens, Y., Felip, E., & ESMO Guidelines Working Group (2010). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21 Suppl 5, v126-8.

Stanic, S., Paulus, R., Timmerman, R. D., Michalski, J. M., Barriger, R. B., Bezjak, A., Videtic, G. M., & Bradley, J. (2014). No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. International Journal of Radiation Oncology, Biology, Physics, 88(5), 1092-9.

Stevens, T. M., Morlote, D., Xiu, J., Swensen, J., Brandwein-Weber, M., Miettinen, M. M., Gatalica, Z., & Bridge, J. A. (2019). NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum. Modern Pathology, 32(6), 764-773.

Stovold, R., Blackhall, F., Meredith, S., Hou, J., Dive, C., & White, A. (2012). Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer, 76(3), 263-8.

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., ... NETTER-1 Trial Investigators (2017). Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 376(2), 125-135.

Strøm, H. H., Bremnes, R. M., Sundstrøm, S. H., Helbekkmo, N., Fløtten, O., & Aasebø, U. (2013). Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. British Journal of Cancer, 109(6), 1467-75.

Suárez-Piñera, M., Belda-Sanchis, J., Taus, A., Sánchez-Font, A., Mestre-Fusco, A., Jiménez, M., & Pijuan, L. (2018). FDG PET-CT SUVmax and IASLC/ATS/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value. American Journal of Nuclear Medicine and Molecular Imaging, 8(2), 100-109.

Sugarbaker, D. J., Flores, R. M., Jaklitsch, M. T., Richards, W. G., Strauss, G. M., Corson, J. M., DeCamp, M. M., Swanson, S. J., ... Mentzer, S. J. (1999). Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. Journal of Thoracic and Cardiovascular Surgery, 117(1), 54-63.

Suh, J. H. (2010). Stereotactic radiosurgery for the management of brain metastases. New England Journal of Medicine, 362(12), 1119-27.

Suh, Y. J., Park, C. M., Han, K., Jeon, S. K., Kim, H., Hwang, E. J., Lee, J. H., Paeng, J. C., ... Goo, J. M. (2020). Utility of FDG PET/CT for Preoperative Staging of Non-Small Cell Lung Cancers Manifesting as Subsolid Nodules With a Solid Portion of 3 cm or Smaller. AJR. American journal of roentgenology, 214(3), 514-523.

Sun, J. M., Ahn, M. J., Ahn, J. S., Um, S. W., Kim, H., Kim, H. K., Choi, Y. S., Han, J., ... Park, K. (2012). Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?. Lung Cancer, 77(2), 365-70.

Sun, L., Davis, C. W., Hwang, W. T., Jeffries, S., Sulyok, L. F., Marmarelis, M. E., Singh, A. P., Berman, A. T., ... Aggarwal, C. (2020). Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. Clinical Lung Cancer,

Sundstrom, S., Bremnes, R., Brunsvig, P., Aasebo, U., Olbjorn, K., Fayers, P. M., & Kaasa, S. (2005). Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiotherapy and Oncology, 75(2), 141-148.

Sundstrom, S., Bremnes, R., Aasebo, U., Aamdal, S., Hatlevoll, R., Brunsvig, P., Johannessen, D. C., Klepp, O., ... Kaasa, S. (2004). Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. Journal of Clinical Oncology, 22(5), 801-10.

Sørensen, S., Helweg-Larsen, S., Mouridsen, H., & Hansen, H. H. (1994). Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. European Journal of Cancer, 30A(1), 22-7.

Takenaka, D., Ohno, Y., Koyama, H., Nogami, M., Onishi, Y., Matsumoto, K., Matsumoto, S., Yoshikawa, T., & Sugimura, K. (2010). Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients. European Journal of Radiology, 74(3), 458-64.

Tapia Rico, G., Chan, M. M., & Loo, K. F. (2020). The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. Cancer Treatment Reviews, 86, 102011.

Tassinari, D., Scarpi, E., Sartori, S., Tamburini, E., Santelmo, C., Tombesi, P., & Lazzari-Agli, L. (2009). Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest, 135(6), 1596-1609.

Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., ... Lynch, T. J. (2010). Early palliative care for patients with metastatic non-small-cell lung cancer. New England Journal of Medicine, 363(8), 733-42.

Teraoka, S., Fujimoto, D., Morimoto, T., Kawachi, H., Ito, M., Sato, Y., Nagata, K., Nakagawa, A., ... Tomii, K. (2017). Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. Journal of Thoracic Oncology, 12(12), 1798-1805.

Thatcher, N., Nicolson, M., Groves, R. W., Steele, J., Eaby, B., Dunlop, J., McPhelim, J., Nijjar, R., & Ukachukwu, I. (2009). Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. Oncologist, 14(8), 840-847.

Thiis-Evensen, E., & Boyar Cetinkaya, R. (2023). Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021. Journal of Neuroendocrinology, 35(4), e13264.

Tomiyama, N., Yasuhara, Y., Nakajima, Y., Adachi, S., Arai, Y., Kusumoto, M., Eguchi, K., Kuriyama, K., ... Yamada, K. (2006). CT-guided needle biopsy of lung lesions: a survey of severe complication based on 9783 biopsies in Japan. European Journal of Radiology, 59(1), 60-4.

Travis, W. D. (2014). Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thoracic Surgery Clinics, 24(3), 257-66.

Travis, W. D., Brambilla, E., Rami-Porta, R., Vallières, E., Tsuboi, M., Rusch, V., Goldstraw, P., & International Staging Committee (2008). Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 3(12), 1384-90.

Treasure, T., Lang-Lazdunski, L., Waller, D., Bliss, J. M., Tan, C., Entwisle, J., Snee, M., O'Brien, M., ... MARS trialists (2011). Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. The Lancet. Oncology, 12(8), 763-72.

Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., ... Investigators, A. (2023). Overall Survival with Osimertinib in Resected. New England Journal of Medicine, 389(2), 137-147.

Tsuruoka, K., Horinouchi, H., Goto, Y., Kanda, S., Fujiwara, Y., Nokihara, H., Yamamoto, N., Asakura, K., ... Ohe, Y. (2017). PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 108, 115-120.

Turner, M. C., Andersen, Z. J., Baccarelli, A., Diver, W. R., Gapstur, S. M., Pope, C. A., Prada, D., Samet, J., ... Cohen, A. (2020). Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations. CA: A Cancer Journal for Clinicians,

Turrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., Wagner, H., Aisner, S., & Johnson, D. H. (1999). Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New England Journal of Medicine, 340(4), 265-271.

Upadhya, P., Ananthraju, A., Vadala, R., & Mohanty Mohapatra, M. (2021). Endocrine paraneoplastic syndromes in lung cancer: a respiratory physician's perspective. Advances in respiratory medicine, 89(4), 403-412.

Vallieres, E., Shepherd, F. A., Crowley, J., Van Houtte, P., Postmus, P. E., Carney, D., Chansky, K., Shaikh, Z., & Goldstraw, P. (2009). The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 4(9), 1049-1059.

van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., Legrand, C., Bottomley, A., ... Giaccone, G. (2005). Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. Journal of Clinical Oncology, 23(28), 6881-9.

van Meerbeeck, J. P., Kramer, G. W., Van Schil, P. E., Legrand, C., Smit, E. F., Schramel, F., Tjan-Heijnen, V. C., Biesma, B., ... European Organisation for Research and Treatment of Cancer-Lung Cancer Group (2007). Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. Journal of the National Cancer Institute, 99(6), 442-50.

van Thiel, E. R., Surmont, V. F., & van Meerbeeck, J. P. (2011). Malignant pleural mesothelioma: when is radiation therapy indicated?. Expert Review of Anticancer Therapy, 11(4), 551-60.

van Veggel, B., Madeira R Santos, J. F. V., Hashemi, S. M. S., Paats, M. S., Monkhorst, K., Heideman, D. A. M., Groves, M., Radonic, T., ... de Langen, A. J. (2020). Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer, 141, 9-13.

Vellayappan, B., Tan, C. L., Yong, C., Khor, L. K., Koh, W. Y., Yeo, T. T., Detsky, J., Lo, S., & Sahgal, A. (2018). Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases. Frontiers in Oncology, 8, 395.

Veronesi, G., Maisonneuve, P., Bellomi, M., Rampinelli, C., Durli, I., Bertolotti, R., & Spaggiari, L. (2012). Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Annals of Internal Medicine, 157(11), 776-84.

Veronesi, G., Morandi, U., Alloisio, M., Terzi, A., Cardillo, G., Filosso, P., Rea, F., Facciolo, F., ... Spaggiari, L. (2006). Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer, 53(1), 111-5.

Veronesi, G., Novellis, P., Voulaz, E., & Alloisio, M. (2016). Robot-assisted surgery for lung cancer: State of the art and perspectives. Lung Cancer, 101, 28-34.

Vilmann, P., Clementsen, P. F., Colella, S., Siemsen, M., De Leyn, P., Dumonceau, J. M., Herth, F. J., Larghi, A., ... Annema, J. T. (2015). Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer. European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). European Respiratory Journal, 46(1), 40-60.

Vogelius, I. R., & Bentzen, S. M. (2012). A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncologica, 51(8), 975-83.

Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., ... Paoletti, P. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology, 21(14), 2636-2644.

von Meyenfeldt, E. M., Prevoo, W., Peyrot, D., Lai A Fat, N., Burgers, S. J., Wouters, M. W., & Klomp, H. M. (2011). Local progression after radiofrequency ablation for pulmonary metastases. Cancer, 117(16), 3781-7.

von Pawel, J., Gatzemeier, U., Pujol, J. L., Moreau, L., Bildat, S., Ranson, M., Richardson, G., Steppert, C., ... Ross, G. (2001). Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. Journal of Clinical Oncology, 19(6), 1743-1749.

von Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., Clark, P. I., ... Gralla, R. (1999). Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. Journal of Clinical Oncology, 17(2), 658-667.

von Plessen, C., Bergman, B., Andresen, O., Bremnes, R. M., Sundstrom, S., Gilleryd, M., Stephens, R., Vilsvik, J., ... Sorenson, S. (2006). Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. British Journal of Cancer, 95(8), 966-73.

Wahidi, M. M., Govert, J. A., Goudar, R. K., Gould, M. K., McCrory, D. C., & American College of Chest Physicians (2007). Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 94S-107S.

Wahl, S. G. F., Dai, H. Y., Emdal, E. F., Berg, T., Halvorsen, T. O., Ottestad, A. L., Lund-Iversen, M., Brustugun, O. T., ... Richardsen, E. (2021). The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study. Cancers, 13(17)

Waite, K., & Gilligan, D. (2007). The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clinical Oncology (Royal College of Radiologists), 19(3), 182-7.

Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S. H., Gao, S., Chen, K. N., Dooms, C., ... Investigators, K. (2023). Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. New England Journal of Medicine, 389(6), 491-503.

Waldeland, E., Brustugun, O. T., Ramberg, C., & Helland, Å. (2012). Stereotaktisk bestråling av columnametastaser. Tidsskrift for den Norske Legeforening, 132(22), 2478-9.

Walji, N., Chan, A. K., & Peake, D. R. (2008). Common acute oncological emergencies: diagnosis, investigation and management. Postgraduate Medical Journal, 84(994), 418-427.

Wang, C., Wang, W., Liu, H., Chen, Q., Chen, C., Liu, L., Zhang, P., Zhao, G., ... Yue, D. (2026). Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial. Annals of Oncology, 37(4), 544-554.

Wang, E. H., Corso, C. D., Rutter, C. E., Park, H. S., Chen, A. B., Kim, A. W., Wilson, L. D., Decker, R. H., & Yu, J. B. (2015). Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 33(25), 2727-34.

Wang, J., Lu, S., Yu, X., Hu, Y., Zhao, J., Sun, M., Yu, Y., Hu, C., ... Zheng, W. (2024). Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial. ESMO Open, 9(10), 103727.

Watanabe, S. M., Nekolaichuk, C. L., & Beaumont, C. (2012). The Edmonton Symptom Assessment System, a proposed tool for distress screening in cancer patients: development and refinement. Psycho-Oncology, 21(9), 977-85.

Weder, W., Stahel, R. A., Bernhard, J., Bodis, S., Vogt, P., Ballabeni, P., Lardinois, D., Betticher, D., ... Swiss Group for Clinical Cancer Research (2007). Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Annals of Oncology, 18(7), 1196-202.

Wei, M. L., Kang, D., Gu, L., Qiu, M., Zhengyin, L., & Mu, Y. (2013). Chemotherapy for thymic carcinoma and advanced thymoma in adults. Cochrane Database of Systematic Reviews, 8, CD008588.

Weir-McCall, J. R., Harris, S., Miles, K. A., Qureshi, N. R., Rintoul, R. C., Dizdarevic, S., Pike, L., Cheow, H. K., & Gilbert, F. J. (2021). Impact of solitary pulmonary nodule size on qualitative and quantitative assessment using 18F-fluorodeoxyglucose PET/CT: the SPUTNIK trial. European Journal of Nuclear Medicine and Molecular Imaging, 48(5), 1560-1569.

Westphalen, C. B., Krebs, M. G., Le Tourneau, C., Sokol, E. S., Maund, S. L., Wilson, T. R., Jin, D. X., Newberg, J. Y., ... de Braud, F. (2021). Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ precision oncology, 5(1), 69.

White, C. S., & Rubin, G. D. (2020). The Puzzle of the Perifissural Nodule. Radiol Cardiothorac Imaging, 2(4), e200409.

Wijn, D. H., Groeneveld, G. H., Vollaard, A. M., Muller, M., Wallinga, J., Gelderblom, H., & Smit, E. F. (2018). Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. European Journal of Cancer, 104, 182-187.

Wilson, J. M., & Jungner, Y. G. (1968). [Principles and practice of mass screening for disease]. Boletín de la Oficina Sanitaria Panamericana, 65(4), 281-393.

Wilson, L. D., Detterbeck, F. C., & Yahalom, J. (2007). Clinical practice. Superior vena cava syndrome with malignant causes. New England Journal of Medicine, 356(18), 1862-1869.

Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., ... Shepherd, F. (2005). Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. New England Journal of Medicine, 352(25), 2589-97.

Wirth, L. J., Carter, M. R., Jänne, P. A., & Johnson, B. E. (2004). Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer, 44(2), 213-20.

Wolf, J., Helland, Å., Oh, I. J., Migliorino, M. R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazieres, J., ... Novello, S. (2022). Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open, 7(1), 100333.

Wolf, J., Seto, T., Han, J. Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., ... GEOMETRY mono-1 Investigators (2020). Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. New England Journal of Medicine, 383(10), 944-957.

Wolfson, A. H., Bae, K., Komaki, R., Meyers, C., Movsas, B., Le Pechoux, C., Werner-Wasik, M., Videtic, G. M., ... Choy, H. (2011). Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics, 81(1), 77-84.

Wolin, E. M. (2017). Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung. Chest, 151(5), 1141-1146.

Wu, D., Liu, Y. Y., Wang, T., Huang, Y. Y., & Xia, P. (2023). Computed tomography-guided lung biopsy with rapid on-site evaluation for diagnosis of lung lesions: a meta-analysis. Journal of Cardiothoracic Surgery, 18(1), 122.

Wu, J. Y., Yu, C. J., & Shih, J. Y. (2019). Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 20(6), e620-e630.

Wu, Y. L., Ahn, M. J., Garassino, M. C., Han, J. Y., Katakami, N., Kim, H. R., Hodge, R., Kaur, P., ... Mok, T. S. K. (2018). CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). Journal of Clinical Oncology, 36(26), 2702-2709.

Wu, Y. L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., ... Mok, T. S. (2017). Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet. Oncology, 18(11), 1454-1466.

Wu, Y. L., Dziadziuszko, R., Ahn, J. S., Barlesi, F., Nishio, M., Lee, D. H., Lee, J. S., Zhong, W., ... Investigators, A. (2024). Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 390(14), 1265-1276.

Wu, Y. L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., ... ADAURA Investigators (2020). Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. New England Journal of Medicine, 383(18), 1711-1723.

Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., Yamanaka, K., Sato, Y., & Jokura, H. (2014). Stereotactic radiosurgery for patients with brain metastases - authors' reply. The Lancet. Oncology, 15(7), e248.

Yang, B., Lee, H., Um, S. W., Kim, K., Zo, J. I., Shim, Y. M., Jung Kwon, O., Lee, K. S., ... Kim, H. (2019). Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. Lung Cancer, 129, 28-34.

Yang, J. C., Schuler, M., Popat, S., Miura, S., Heeke, S., Park, K., Märten, A., & Kim, E. S. (2020). Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Journal of Thoracic Oncology, 15(5), 803-815.

Yang, J. C., Sequist, L. V., Geater, S. L., Tsai, C. M., Mok, T. S., Schuler, M., Yamamoto, N., Yu, C. J., ... Wu, Y. L. (2015). Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. The Lancet. Oncology, 16(7), 830-8.

Yang, S. Y., Kim, D. G., Lee, S. H., Chung, H. T., Paek, S. H., Hyun Kim, J., Jung, H. W., & Han, D. H. (2008). Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. Cancer, 112(8), 1780-6.

Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., ... RAD001 in Advanced Neuroendocrine Tumours, F. u. T. (. S. G. (2016). Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, 387(10022), 968-977.

Yokoba, M., Ichikawa, T., Harada, S., Naito, M., Sato, Y., & Katagiri, M. (2018). Postoperative pulmonary function changes according to the resected lobe: a 1-year follow-up study of lobectomized patients. Journal of Thoracic Disease, 10(12), 6891-6902.

Yuen, A. R., Zou, G., Turrisi, A. T., Sause, W., Komaki, R., Wagner, H., Aisner, S. C., Livingston, R. B., ... Johnson, D. H. (2000). Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer, 89(9), 1953-1960.

Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., ... French Cooperative Thoracic Intergroup (IFCT) (2016). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, 387(10026), 1405-14.

Zeng, H., De Ruysscher, D., X, H., Zheng, D., Yang, L., Ricardi, U., Kong, F., & Hendriks, L. (2022). Radiotherapy for small cell lung cancer in current clinical practice guidelines. Journal of the National Cancer Center, 2(2), 113-125.

Zhao, C., & Rajan, A. (2019). Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?. Mediastinum, 3

Zhou, C., Solomon, B., Loong, H. H., Park, K., Pérol, M., Arriola, E., Novello, S., Han, B., ... Investigators, L. T. (2023). First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. New England Journal of Medicine, 389(20), 1839-1850.

Zhou, C., Tang, K. J., Cho, B. C., Liu, B., Paz-Ares, L., Cheng, S., Kitazono, S., Thiagarajan, M., ... Investigators, P. (2023). Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. New England Journal of Medicine, 389(22), 2039-2051.

Zhu, Z., Ni, J., Cai, X., Su, S., Zhuang, H., Yang, Z., Chen, M., Ma, S., ... Fu, X. (2022). International consensus on radiotherapy in metastatic non-small cell lung cancer. Translational lung cancer research, 11(9), 1763-1795.